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        Melanoma is the most malignant form of skin cancer. The five-year survival 
rate for metastatic melanoma is 19.9%. Although targeted therapy of BRAF and 
MEK inhibitors were developed for melanoma, resistance to therapy is inevitable. 
Immune checkpoint blockade, which reverses the suppression of the immune 
system, on the other hand, has shown a durable response in 20-30% of patients 
with metastatic melanoma. However, more predictive and robust biomarkers of 
response to this therapy are still needed, and resistance mechanisms remain 
incompletely understood. To address this, we examined a cohort of metastatic 
melanoma patients treated with sequential checkpoint blockade against cytotoxic 
T lymphocyte antigen–4 (CTLA-4) followed by programmed death receptor–1 
(PD-1) by immunogenomic profile analyses from serial tumor biopsies. 
        From immune profiling (12 marker immunohistochemistry and NanoString 
Gene Expression Profiling), we found that adaptive immune signatures in tumor 
biopsies obtained from early on-treatment time points are predictive of response 
to immune checkpoint blockade. We also demonstrated differential mechanistic 
	   viii	  
signatures of tumor microenvironment induced by CTLA-4 and PD-1 blockade. 
Importantly, VEGFA was identified as a potential target of combination therapy 
with PD-1 blockade. 
        From genomic profiling (whole exome sequencing and T cell receptor 
sequencing), we demonstrated that a higher TCR clonality in pre-treatment 
biopsy was predictive of response to PD-1 but not CTLA-4 blockade. We also 
observed increased TCR clonality after CTLA-4 blockade treatment in patients 
responding to the following PD-1 blockade treatment. Analysis of copy number 
alterations (CNAs) identified a higher burden of copy number loss in 
nonresponders to CTLA-4 and PD-1 blockade and found that it was associated 
with decreased expression of genes in immune-related pathways. The effect of 
mutational load and burden of copy number loss on response was nonredundant, 
suggesting the potential utility of these as a combinatorial biomarker to optimize 
patient care with checkpoint blockade therapy. 
        In summary, our integrative cancer immunogenomic analysis shows that 
genomic and immune profiling of longitudinal tumor biopsies can identify novel 
biomarkers and resistance mechanisms of immune checkpoint blockade.   
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Chapter 1 INTRODUCTION  
1.1 Melanoma  
        Melanoma is a malignancy of melanocytes, the melanin-producing cells of 
neuroectodermal origin (1). Melanocytes can be found throughout the body 
including the skin, iris, and rectum, and melanocytes at different sites can 
develop into phenotypically diverse malignancies. The cutaneous form of 
melanoma is common in the Western world and contributes 75% of deaths from 
skin cancer (2). The major risk factor for cutaneous melanoma is UV exposure. 
Therefore, a typical UV exposure signature, C-to-T transition, is frequently 
observed in the mutational signatures of cutaneous melanoma. Due to mutagenic 
effect of UV radiation, cutaneous melanoma has a high mutation rate of 16.8 
mutations/Mb (3).    
        Sequencing studies of melanoma have identified melanoma driver genes 
involved in mitogen-activated protein kinase (MAPK) and other signaling 
pathways (4-6). The most common genetic alterations occur in BRAF and NRAS, 
which leads to MAPK pathway hyperactivation (7, 8). Amplification of AKT3 by 
copy number increases and loss of PTEN by deletion are also recurrent genetic 
alterations (9, 10). The recent The Cancer Genome Atlas (TCGA) study of 
cutaneous melanoma further identified four subtypes based on genomic 
classification: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type) 
(11).    
        The identification of genetic alterations in melanoma led to development of 
targeted therapies. The first targeted therapy for melanoma was a BRAF 
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inhibitor. In phase III clinical trial of vemurafenib (a BRAF inhibitor) in BRAF 
V600E-mutant melanoma patients, an overall response rate was 48% with a 
survival advantage compared to chemotherapy of dacarbazine (12). Dabrafenib 
(another BRAF inhibitor) showed similar clinical benefit (13). Vemurafenib and 
dabrafenib were approved by the U.S. Food and Drug Administration (FDA) for 
treatment of advanced BRAF-mutant melanoma patients. However, the response 
to targeted therapy was transient with median progression-free survival of 5 to 7 
months due to intrinsic and acquired resistance mechanisms (12-14). The first-
line BRAF/MEK combination therapy showed an overall response rate of 67%, 
which is significant improvement in response rates compared to BRAF 
monotherapy, but the median progression-free survival was only 9.3 months (15). Although there has been considerable amount of efforts to overcome drug 
resistance for targeted therapies in melanoma, durability of clinical response is 
still limited. 
 
1.2 Cancer immunology and immune checkpoint blockade (ICB) 
1.2.1 Cancer Immunology 
        Cancer is a genetic disease. Tumor cells support their growth by mutations 
activating oncogenes or suppressing tumor suppressor genes. However, factors 
extrinsic to cancer cells, such as the immune system, can also affect their fate as 
they evolve over their lifetime under the selective pressure from tumor 
microenvironment. For instance, cancer cells can be recognized as ‘foreign’ by 
the immune system due to the mutated peptides presented by cancer cells on 
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their cell surface. Therefore, the tumor is visible to the immune system and the 
immune system can act as a critical selective pressure in tumor 
microenvironment. 
        The interaction between cancer and the immune system can be explained 
by the ‘cancer-immunity cycle’ (16). In the first step, peptides containing mutated 
amino acid residues (neoantigens) produced by mutations in cancer cells are 
released and captured by dendritic cells (DCs). Then, DCs present these 
antigens on MHC I and MHC II molecules to T cells. This leads to the priming 
and activation in effector T cells with antigen specificity. Next, the activated 
effector T cells traffic to and infiltrate into tumor sites, resulting in recognition of 
cancer cells through interaction between TCR and MHC-bound antigen on the 
surface of cancer cells. Finally, the activated effector T cells can kill their target 
cancer cell. Death of cancer cells releases additional tumor-associated antigens 
providing fuel for the next round of cancer-Immunity cycle.     
        However, the cancer-immunity cycle is not always continuous. The flow of 
cancer-immunity cycle is tightly controlled by balance between positive regulators 
and negative regulators. Positive regulators can be tumor intrinsic (cytokine 
secretion, genetic composition) or extrinsic (gut microbiota composition and 
infection status, exposure to sunlight). Checkpoint molecules are examples of 
negative regulators in the cancer-immunity cycle. The equilibrium between 
positive and negative regulators is termed ‘cancer-immune set point’ (17). The 
threshold of cancer-immunity set point should be surpassed for the immune 
system to eliminate target cancer cells. 
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        According to the cancer immunoediting theory (18), cytotoxic antigen-
specific T cells can recognize and eliminate subclinical tumors, but at some point 
the tumor remains in situ in a state of equilibrium. Then, most tumors can escape 
from equilibrium and become clinically visible. Therefore, effective 
immunotherapy should aim to lower the threshold of cancer-immune set point by 
activating positive regulators of cancer-immunity cycle or by suppressing 
negative regulators of cancer-immunity cycle. 
 
1.2.2 Immune Checkpoint Blockade (ICB) 
        The diversity, specificity, and memory of the immune cells that target tumor 
cells expressing tumor-associated-antigens and neoantigens (non-self peptides 
resulting from exonic missense mutations) are unique features that are 
harnessed in immunotherapy strategies (19). Melanoma is particularly 
responsive to immunotherapy due to the high infiltration of immune cells into 
tumors and potentially, the greater number of neoantigens that are presented 
due to its high mutation burden (3). However, the natural balance between 
cancer and immune cells is tolerance (the failure to mount an immune response) 
and thus cancer cells can evade immune surveillance (20). The tolerance 
mechanisms can be immunosuppressive cytokines and chemokines, regulatory 
immune cells, and immune checkpoint pathways suppressing immune activation. 
Among several ways to reverse tolerance are the immune checkpoint blockades 
(ICB) (CTLA-4 blockade, PD-1 blockade), antibodies blocking the negative 
signals of T cell activation. ICB is recognized as breakthrough cancer 
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immunotherapy. The first FDA-approved agent ICB was ipilimumab, an antibody 
against CTLA-4, which showed long-term survival for 20% of melanoma patients 
(21). More recently, PD-1 blockade (nivolumab and pembrolizumab) has been 
approved with response rates between 28% and 40% (22, 23).    
 
1.3 Cancer immunogenomics  
1.3.1 Next-generation sequencing (NGS) 
        Next-generation sequencing (NGS) technologies have changed the 
landscape of cancer research and clinical care by enabling identification of 
alterations at the base-pair resolution in cancer patients. From NGS 
technologies, multiple variants (single nucleotide variants, small insertions and 
deletions, copy number variants, structural variants and gene fusions), gene 
expression, and DNA methylation can be profiled in a genome-wide scale from a 
same sample. Therefore, multidimensional profiling of genome, transcriptome, 
and epigenome from individual patients becomes feasible. A genomic directed 
approach of tailoring cancer therapy to individual patients (precision oncology) is 
currently being implemented in many centers. The application of NGS 
technologies (whole exome sequencing, RNA-seq, and bisulfite sequencing for 
DNA methylation) and computational pipelines can build major databases for 
cancer immunogenomics (24). For example, in addition to the multidimensional 
profiling data generated from our study, we could download and analyze the 
publicly available genomic data (whole exome sequencing and RNA-seq) from 
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an independent cohort of melanoma patients treated with CTLA-4 blockade, 
termed Van Allen cohort in our study (25). 
 
1.3.2 Characterization of immune infiltrates  
        The composition of tumor-infiltrating lymphocytes (TILs) can affect tumor 
progression (26). Therefore, cellular characterization of TILs can provide a 
framework for discovery of prognostic and predictive markers. A large number of 
bioinformatics tools have been developed to quantify the cellular composition of 
TILs from transcriptome data. One approach is gene set enrichment analysis 
(GSEA) which can evaluate ranked gene list for enrichment of certain pathways 
and cellular processes (27). Immunological signatures (ImmuneSigDB) can be 
used with GSEA to characterize cellular composition of TILs from transcriptome 
data. Another approach is deconvolution method which uses cell type-specific 
expression signature matrix to infer cellular composition of TILs. Several 
algorithms (DeconRNASeq, CIBERSORT, and TIMER) were developed for this 
purpose (28-30).  
 
1.3.3 In silico prediction of neoantigens  
        Neoantigens are somatic mutations in the cancer genome that can be 
presented and recognized by the immune system as foreign. From NGS data, we 
can profile predicted neoantigens in silico by three steps: identification of 
predicted mutated peptides, HLA typing, and prediction of binding affinity 
between neoantigens and MHC molecules. First, somatic mutations are called 
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from somatic variant callers. Then, the DNA sequences spanning somatic point 
mutations are virtually translated into the mutated “peptides” with amino acid 
sequence length ranging between 8 and 11 (31). Next, HLA typing can be 
performed from NGS data by several computational methods including 
Polysolver (32) and Optitype (33). Finally, binding affinity between virtually 
translated mutated peptides and patient-specific HLA molecules can be predicted 
by neural network algorithms trained on data from the Immune Epitope Database 
(IEDB) (34). Mutated peptides with predicted binding affinity below IC50 value of 
500nM are generally considered as predicted neoantigens (31). 
 
1.3.4 T cell receptor (TCR) profiling 
        T lymphocytes of the adaptive immune system can recognize foreign 
molecules through antigen binding receptors. The diversity of immune repertoire 
can be obtained by V(D)J recombination, which is the somatic recombination of 
gene segments in the variable (V), diversity (D), and joining (J) loci. Further 
diversification occurs by the addition or removal of random nucleotides at the 
junction sites and by combination of α and β subunits. Antigen-specificity is 
largely determined by the complementary-determining regions 3β (CDR3β), 
which is the junctional site of V(D)J recombination, because this region accounts 
for the most variability in T cell repertoire. T cells with the same CDR3β are 
considered as the same clone. 
        TCR sequencing is a targeted repertoire sequencing of the TCR locus. 
MiXCR algorithm (35) can extract CDR3β sequences from TCR sequencing data 
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and profile the type and frequency of T cell clones in a person’s T cell repertoire. 
TRUST algorithm (36) can also detect TCR hyper-variable region sequences 
from RNA-seq data. Once all the T cell clones are profiled, diversity of T cell 
repertoire and clonal expansion of T cell clones can be characterized.   
 
1.4 Biomarkers and resistance mechanisms of immune checkpoint 
blockade (ICB) 
1.4.1 Known biomarkers and resistance mechanisms of ICB 
        Response rates to immune checkpoint blockade (ICB) can be modest but 
are often durable (21-23). Therefore, there are ongoing efforts to identify 
biomarkers that predict patient response to ICB. First, it is important to 
understand how tumor cell intrinsic factors and extrinsic factors of tumor 
immunogenicity contribute to resistance to ICB (37). Tumor cell intrinsic factors 
include the mechanisms involved with tumor antigens and interaction with T cells. 
Absence of antigenic proteins due to low mutational load, lack of viral antigens, 
or lack of cancer-testis antigens is one of the tumor cell intrinsic factors (25, 38-
41). Absence of antigen presentation due to alterations in antigen presentation 
pathways can also contribute to resistance (40). Other tumor-intrinsic 
mechanisms include genetic T cell exclusion (42-44) and loss of interferon-
gamma signaling pathways (45-47). Tumor cell extrinsic factors include absence 
of T cells due to lack of T cells with tumor antigen-specific TCRs (48), expression 
of inhibitory immune checkpoints such as VISTA, LAG-3, and TIM-3 (49, 50), 
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presence of immunosuppressive cells such as tumor-associated macrophages 
and regulatory T cells (51, 52), and gut microbiota composition (53).  
        Biomarker discovery can be aided by mechanistic insights from resistance 
mechanisms. Tumor cell intrinsic factors are closely related with genetic 
biomarkers and tumor cell extrinsic factors are closely related with immunological 
biomarkers. For example, high mutational load and neoantigen load (tumor cell 
intrinsic factors) were associated with response to ICB (25, 38-41), and high 
CD8+ T cell density at the invasive tumor margin and high TCR clonality (tumor 
cell extrinsic factors) were correlated with response to PD-1 blockade TCR 
clonality (48).  
        Additionally, resistance mechanisms can provide insights into new 
biomarker discovery. For example, the resistance mechanism by absence of 
antigenic proteins due to low mutational load suggested that the tumor types with 
defects in DNA mismatch repair complex (MMR) might show higher response to 
ICB due to their higher mutational load. These tumor types can be detected with 
microsatellite instability (MSI) or with the absence of a single MMR protein by 
immunohistochemistry. Notably, MMR-deficient tumors have 10- to 100-fold 
higher mutational load than MMR-proficient tumors. Since MMR deficiency 
confers high mutational load in tumors, it was hypothesized that MSI phenotype 
would be associated with increased antitumor immunity. As predicted, MSI colon 
cancers showed high infiltration of T cells relative to microsatellite stable (MSS) 
colon cancers (54), and the clinical response of colorectal cancer patients treated 
with PD-1 blockade was higher in patients with MSI phenotype than those with 
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MSS phenotype (55). In line with these results, FDA recently approved PD-1 
blockade treatment for cancer patients with microsatellite instability-high (MSI-H) 
or mismatch repair deficient (dMMR). The example of FDA approval of MSI-H 
and dMMR as a biomarker for PD-1 blockade treatment shows that 
understanding of resistance mechanisms can help discovery of novel 
biomarkers.  
 
1.4.2 Potential biomarkers and resistance mechanisms of ICB 
        There is an active ongoing effort for discovering novel genetic and 
immunological biomarkers predictive of clinical benefit to ICB. Intratumor 
heterogeneity (ITH) is generally associated with drug resistance and worse 
prognosis (56-58) and several studies have investigated the implication of ITH in 
cancer immunotherapy. One study reported that ITH is associated with 
expression of immunomodulators and enrichment of immune cell subtypes in 
colorectal cancer (59). Another study showed that a high burden of clonal 
neoantigens was correlated with better prognosis, increased immune cell 
infiltration into tumors, and a durable response to immunotherapy (60). 
Therefore, I hypothesized that ITH might also confer resistance to immune 
checkpoint blockade in melanoma. In addition to ITH, I further investigated 
somatic HLA mutations because recent pan-cancer study showed the evidence 
of recurrent somatic HLA mutations as immune escape mechanism (32). I also 
extensively investigated copy number alterations because previous studies 
mostly focused on only somatic point mutations and mutational load. 
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1.4.3 Integrative and longitudinal approach for discovery of biomarkers and 
resistance mechanisms of ICB 
        Previous studies have focused on identifying genetic biomarkers and 
immunological biomarkers independently. Therefore, there is lack of information 
about mechanistic link between genetic and immunological biomarkers. In this 
study, we generated patient-matched genomic (whole exome sequencing, TCR 
sequencing) and immune (12 marker immunohistochemistry, NanoString Gene 
Expression Profiling) profiling data. Therefore, our patient-matched genomic and 
immune profiling data provided novel insight into the interaction between cancer 
and the immune system.  
        Our study was also unique in that longitudinal tumor biopsies (pre-, on-, and 
post-treatment) were analyzed for discovery of biomarkers and resistance 
mechanisms of ICB. By comparing on-/post-treatment samples with pre-
treatment samples, we could investigate dynamic change in mechanistic 
signatures and adaptive resistance signatures after treatment.  
 
1.5 Hypothesis, specific aims and rationale 
        My hypothesis is that integrative and longitudinal analysis of genomic and 
immune profiling data can provide predictive signatures and mechanistic 
signatures for response and resistance of sequential immune checkpoint 
blockade treatment (CTLA-4 blockade followed by PD-1 blockade). The primary 
objective of this study is to discover genetic and immunological biomarkers for 
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immune checkpoint blockade response and elucidate resistance mechanisms to 
find potential strategies to overcome them and increase response rate to immune 
checkpoint blockades. 
 
Specific Aims 
I tested the hypothesis by the following specific aims: 
Aim 1) Determine the immunological biomarkers and resistance mechanisms of 
immune checkpoint blockade 
Aim 2) Determine the genetic biomarkers and resistance mechanisms of immune 
checkpoint blockade 
Aim 3) Investigate the molecular interplay between the immune system and cancer 
under immune checkpoint blockade 
 
Rationale: Blockade of T cell coinhibitory molecules such as CTLA-4 and PD-1, 
can activate T cell antitumor response. Although the immune checkpoint 
blockades (CTLA-4 blockade and PD-1 blockade) have shown durable response 
in metastatic melanoma, response rate is modest. Therefore, there is a pressing 
need to find stable biomarkers predictive of response to immune checkpoint 
blockades and to understand underlying resistance mechanisms. We collected 
longitudinal (pre-/on-/post-treatment) tumor biopsies from a cohort of metastatic 
melanoma patients treated with sequential immune checkpoint blockade and 
performed multidimensional genomic and immune profiling of this cohort. We aim 
to discover stable biomarkers and resistance mechanisms by identifying the 
predictive signatures from pre-treatment biopsies and the mechanistic signatures 
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that change during treatment from longitudinal biopsies. Multidimensional 
approach of genomic and immune profiling can allow discovery of novel 
combinatorial biomarkers, mechanistic insights into the interaction between 
tumors and the immune system, and understanding of how their interaction leads 
to differential response to immune checkpoint blockade.  
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Chapter 2 MATERIALS AND METHODS  
2.1 Patient Cohort and Tumor Samples 
2.1.1 Study design 
        Serial tumor biopsies were collected from patients with metastatic 
melanoma treated with CTLA-4 blockade and/or PD-1 blockade through the 
Expanded Access Program for MK-3475 at the UT MD Anderson Cancer Center. 
From serial tumor biopsies, we generated multidimensional profiling data (whole 
exome sequencing data, TCR sequencing data, and NanoString gene expression 
profiling). These data were analyzed to identify genomic and immune correlates 
of treatment response and resistance mechanisms of immune checkpoint 
blockade. 
 
2.1.2 Patient cohort and tumor samples 
        A cohort of 56 patients with metastatic melanoma were included in this 
study. These patients were treated at the UT MD Anderson Cancer Center 
between October 2011 and March 2015 and had tumor samples collected with 
appropriate written informed consent and analyzed (IRB LAB00-063; LAB03-
0320; 2012-0846; PA13-0291; PA12-0305). All tumor measurements were 
performed by a physician formally trained in tumor metrics, specifically RECIST 
1.1 (61) as it applies to the cohort. All metrics used computerized axial 
tomography scan imaging of measurable lesions (5 lesions total and 2 per organ 
max.) that met measurability based on strict RECIST 1.1 criteria (i.e > 10mm long 
axis per target lesion or > 15mm short axis for target lymph nodes). The sum of 
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these respective diameters were compared to the sum at baseline. Per RECIST 
1.1 criteria a lymph node < 10mm short axis was considered non-pathologic. As 
such patients were first defined at those having either a (1) complete response 
(disappearance of ALL target lesions, reduction in any pathological lymph nodes 
(whether target or not) in short axis to <10 mm, and the appearance of NO new 
lesions), (2) partial response (at least a 30% decrease in the sum of diameters of 
target lesions, no PD in non-target lesions and the appearance of NO new 
lesions), (3) progressive disease (at least a 20% increase in the sum of 
diameters of target lesions, taking as reference the smallest sum or baseline, 
with a minimum absolute increase of 5mm, and/or the development of any new 
lesions), or (4) stable disease [neither sufficient decrease to designate complete 
response (CR)/partial response (PR) nor increase to qualify as progressive 
disease (again using as a reference the smallest sum of appropriate diameters)]. 
All image responses were vetted with ≥2 serial images over a ≥6 month interval 
between baseline and assignment of response. RECIST 1.1 quantification of 
response was then used to assign patient designation as responder (i.e. CR, PR, 
or stable disease (SD) ≥6 months) or non-responder (progressive disease (PD) 
or SD < 6 months duration). All specimens were excisional biopsies or resection 
specimens.  
 
2.2 Immune Profiling 
2.2.1 Immune profiling by IHC 
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        Tumor samples (n=88) were formalin-fixed and paraffin-embedded, 
including pretreatment anti–CTLA4 (n=36; 5 responders and 31 nonresponders), 
on-treatment anti-CTLA4 (n=5; 2 responders and 3 nonresponders), progression 
anti-CTLA4 (n=22), pretreatment anti–PD-1 (n=24; 7 responders and 17 
nonresponders), on-treatment anti–PD-1 (doses 2–3; n=11; 5 responders and 6 
nonresponders), and progression anti–PD-1 (n=12) biopsies. To examine the 
effect of CTLA4 blockade on pretreatment and on-treatment PD-1 blockade 
biopsies, additional immune profiling analysis by IHC was performed on a 
separate cohort of patients treated with PD-1 blockade who were CTLA4 
blockade–naïve (n = 13), including pretreatment anti–PD-1 (n=9; 7 responders 
and 2 nonresponders) and on-treatment anti–PD-1 (n=4; 2 responders and 2 
nonresponders) biopsies. From each tissue block, a hematoxylin and eosin–
stained slide was examined to evaluate tumor cellularity. IHC was performed 
using an automated stainer (Leica Bond Max, Leica Biosystems), and the 
primary antibodies used included CD3 (DAKO, A0452, 1:100), CD4 (Leica 
Biosystems, NCL368, 1:80), CD8 (Thermo Scientific MA5-13473, 1:25), CD20 
(DAKO, L26, 1:1,400), CD45RO (Leica Biosystems, PA0146, ready to use), 
CD57 (BD Biosciences, 347390, 1:40), CD68 (DAKO, MO876, 1:450), FOXP3 
(BioLegend, 320102, 1:50), Granzyme B (Leica Microsystems, PA0291, ready to 
use), LAG3 (LifeSpan Bioscience, 17B4, 1:100), PD-1 (Epitomics, ab137132, 
1:250), PD-L1 (Cell Signaling Technology, 13684, 1:100), CD14 (Abcam, 
Ab133503, 1:100), CD33 (Leica Microsystems, LCD33-L-CE, 1:100), CD163 
(Leica Biosystems, NCL- L-CD163, 1:500), and CD206 (Abcam, Ab64693, 
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1:2,000). All slides were stained using previously optimized conditions with 
appropriate positive and negative controls. The IHC reaction was detected using 
the Leica Bond Polymer Refine detection kit (Leica Biosystems) and 
diaminobenzidine (DAB) was used as chromogen. Counterstaining was done 
using hematoxylin. IHC and hematoxylin and eosin–stained slides were 
converted into high-resolution digital images using an Aperio slide scanner 
(Aperio AT Turbo, Leica Biosystems). The digital images were then analyzed 
using the Aperio Image Toolbox analysis software (Leica Biosystems), Aperio 
image analysis algorithms nuclear and cytoplasmic v9. From each e-slide, 5 × 1 
mm2 areas within the tumor region (except for small biopsy samples) were 
chosen by a pathologist for digital analysis. IHC staining for CD3, CD4, CD8, 
CD20, CD45RO, CD57, CD68, FOXP3, Granzyme B, LAG3, PD-1, CD14, CD33, 
CD163, and CD206 was evaluated as density of cells, defined as the number of 
positive cells per mm2. PD-L1 expression was evaluated in tumor cells using H-
score, which includes the percentage of positive cells showing membrane 
staining pattern (0–100) multiplied by the intensity of the staining (0 to 3+), with a 
total score ranging from 0 to 300. The final score for each marker was expressed 
as the average score of the areas analyzed within the tumor region (tumor 
center). In addition, of the initial cohort of 88 samples scored, 41 samples 
showing discernible tumor margins were evaluated for CD8 density at both tumor 
margin and center. The final scores for each marker from each patient were then 
transferred to a database for statistical analysis. 
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2.2.2 Immunofluorescence 
        For a subset of formalin-fixed and paraffin-embedded samples (n=19), 
immunofluorescence staining was performed for CD8 (Thermo Scientific, MA5-
13473) and CD68 (DAKO, MO876) to investigate potential myeloid–T cell 
interactions, including pretreatment anti-CTLA4 (n=5; 2 responders and 3 
nonresponders), on-treatment anti-CTLA4 (n=2; 1 responder and 1 
nonresponder), pretreatment anti-PD-1 (n=6; 3 responders and 3 nonresponders), 
and on-treatment anti-PD-1 (doses 2–3; n=6; 3 responders and 3 nonresponders) 
biopsies. This was done following the Opal protocol staining method with CD8 in 
Alexa488 (1:50) and CD68 in Alexa594 (1:100). For quantification, each 
individual DAPI-, CD8-, and CD68-stained section was utilized to establish the 
spectral library of fluorophores required for multispectral analysis. Slides were 
scanned using the Vectra slide scanner (PerkinElmer) under fluorescent 
conditions. For each marker, the mean fluorescent intensity per case was then 
determined as a base point from which positive calls could be established. Finally, 
an average of five random areas on each slide were analyzed for contact 
quantification (ratio of number of CD68 cells in contact with CD8 divided by 
number of CD68 cells) blindly by a pathologist at 20× magnification. 
 
2.2.3 NanoString Gene Expression Analysis 
        A subset of tumor samples (n=54) with adequate tissue following immune 
profiling were selected for NanoString analysis using a custom-designed 795-
gene codeset (The gene list can be found from Supplementary Table S5 in Chen, 
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Pei-Ling, et al. "Analysis of immune signatures in longitudinal tumor samples 
yields insight into biomarkers of response and mechanisms of resistance to 
immune checkpoint blockade." Cancer discovery 6.8 (2016): 827-837.). This 
gene codeset includes the genes involved in immune response (Chemokines, 
Cytokines, Cell Functions, B-Cell Functions, Antigen Processing, Regulation, 
Cytotoxicity, NK Cell Functions, Transporter Functions, Pathogen Defense, 
Leukocyte Functions, T-Cell Functions, Adhesion, Complement, Senescence, 
Interleukins, Macrophage Functions, TLR, Microglial Functions, and TNF 
Superfamily) and cancer pathways (Notch, Wnt, HedgeHog, Chromatin 
Modification, Transcriptional Regulation, TGF-B, MAPK, STAT, PI3K, RAS, Cell 
Cycle, and Apoptosis). All tumor samples were prepared from formalin-fixed and 
paraffin-embedded tissue blocks, including pretreatment anti-CTLA4 (n=16; 5 
responders and 11 nonresponders), on-treatment anti-CTLA4 (n=5; 3 responders 
and 2 nonresponders), progression anti-CTLA4 (n=15), pretreatment anti–PD-1 
(n=16; 7 responders and 9 nonresponders), on-treatment anti–PD-1 (doses 2–3; 
n=10; 5 responders and 5 nonresponders), and progression anti–PD-1 (n=7) 
biopsies (Supplementary Tables S1D and S5). Hematoxylin and eosin–stained 
sections were prepared to evaluate tumor cellularity. Total RNA was extracted 
from each sample individually using the RNeasy Mini Kit (QIAGEN). For each 
NanoString assay, 1 µg of total tissue RNA was isolated, mixed with a 
NanoString code set mix, and incubated at 65°C overnight (16–18 hours). The 
reaction mixes were loaded on the NanoString nCounter Prep Station for binding 
and washing, and the resulting cartridge was transferred to the NanoString 
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nCounter digital analyzer for scanning and data collection. A total of 600 fields 
were captured per sample to generate the raw digital counts for each sample. To 
examine the effect of prior CTLA4 blockade on anti–PD-1 pretreatment and on-
treatment tissue samples, a separate gene expression profiling analysis was 
performed using a custom-designed, 795-probe codeset on 28 samples. 
Compared with the initial code set, the β2-microglobulin probe was deleted and 
the Melanoma Inhibitory Activity (MIA) probe was added. The same 
preprocessing, normalization, and statistical analysis of NanoString nCounter 
data were applied to these 28 anti–PD-1 samples, which included 7 pretreatment 
samples (4 responders, 3 nonresponders) and 8 on-treatment samples with prior 
CTLA4 blockade (3 responders, 5 nonresponders), as well as 8 pretreatment 
samples (6 responders, 2 nonresponders) and 5 on-treatment samples (2 
responders, 3 nonresponders) that were CTLA4 blockade–naïve. 
 
2.2.4 Statistical Analysis 
2.2.4.1 Immune Profiling by IHC  
        Analyses were performed using GraphPad Prism software. All tests were 
two-sided, parametric t tests. P values of <0.05 were considered statistically 
significant. 
 
2.2.4.2 NanoString Data Preprocessing  
        Raw count data were preprocessed using NanoStringNorm R package 
NanoStringNorm (62). Specifically, geometric mean–based scaling normalization 
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was performed to account for technical assay variation, followed by background 
adjustment and RNA content normalization via annotated housekeeping genes. 
The most stable set of housekeeping genes (ABCF1, GUSB, TBP, and TUBB) 
was selected by the geNorm algorithm (63). Log2-transformed data were used 
for downstream analyses.  
 
2.2.4.3 Differential Gene Expression Analysis  
        Fold change of each gene was calculated as the ratio of average gene 
expression intensity of the responder group to that of the nonresponder group. A 
two-sample t test was used to compare gene expression intensities between the 
responder group and the nonresponder group. To account for multiple testing, 
False Discovery Rate (FDR) (64), defined as the probability of being true under 
null hypothesis when rejected, was used. The beta-uniform mixture model (65) 
was used to obtain FDR. A gene was claimed to be differentially expressed if it 
showed a fold change of > 2 (increased in responders) or ≤ −1/2 (increased in 
nonresponders) and FDR ≤ 0.05. Volcano plots were used to visualize log2 fold 
change on the x-axis and P values on the y-axis. Each gene was color-coded 
based on its fold change and FDR. This analysis was performed at individual 
time points (pre–anti-CTLA4, on–anti-CTLA4, pre–anti-PD-1, and on–anti-PD-1 
treatment). 
 
2.2.4.4 Assessment of Time-by-Response Interaction  
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        A linear mixed effects model, implemented using R package lme4, was 
used to evaluate interactions between “Time (pretreatment, on-treatment)” and 
“Response (responders, nonresponders)” on gene expression intensity (66). In 
this model, the covariates of time, response, and time-by-response interactions 
were included as the fixed effects and a patient-specific random intercept was 
assumed to follow a mean 0 normal distribution. Again, an FDR threshold of 0.05 
was used to select genes with significant interaction between time and response. 
Genes with positive interaction coefficients showed upregulated expression in 
responders or downregulated expression in nonresponders after a treatment, 
whereas genes with negative interaction coefficients showed downregulated 
expression in responders or upregulated expression in nonresponders after a 
treatment. Volcano plots were used to visualize the interaction coefficients on the 
x-axis and P values on the y-axis. Each gene was color-coded based on its 
interaction coefficients and FDR.  
 
2.3 Genomic Profiling 
2.3.1 Sample processing 
        After fixation and mounting, 5 to 10 slices of 5 µm thickness were obtained 
from formalin-fixed, paraffin-embedded (FFPE) tumor blocks. Tumor-enriched 
tissue was macrodissected, and Xylene (EMD Millipore) was used for 
deparaffinization, followed by two ethanol washes. Reagents from the Qiagen 
QIAamp DNA FFPE Tissue Kit (#56404) were used in conjunction with an 
overnight incubation at 55°C to complete tissue lysis. Next, samples were 
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incubated at 90°C for one hour to reverse formaldehyde modification of nucleic 
acids. After isolation by QIAamp MinElute column, variable amounts of buffer 
ATE were added to each column to elute the DNA. Germline DNA was obtained 
from peripheral blood mononuclear cells (PBMCs). 
 
2.3.2 Whole exome sequencing 
        The initial genomic DNA input into the shearing step was 250 ng in 55 µL of 
low Tris-EDTA buffer. Forked Illumina paired-end adapters with random 8 base 
pair indexes were used for adapter ligation. All reagents used for end repair, A-
base addition, adapter ligation, and library enrichment PCR were from the KAPA 
Hyper Prep Kit (#KK8504). Unligated adapter and/or adapter-dimer molecules 
were removed from the libraries before cluster generation using SPRI bead 
cleanup. The elution volume after post-ligation cleanup was 25 µL. Library 
construction was performed following manufacturer's instructions. Sample 
concentrations were measured after library construction using the Agilent 
Bioanalyzer. Each hybridization reaction contained 650-750 ng of the prepared 
library in a volume of 3.4 µL. Samples were lyophilized and reconstituted to bring 
the final concentration to 221 ng/µL. After reconstitution, the Agilent SureSelect-
XT Target Enrichment (#5190-8646) protocol was followed, according to 
manufacturer guidelines. The libraries were then normalized to equal 
concentrations using an Eppendorf Mastercycler EP Gradient instrument and 
pooled to equimolar amounts on the Agilent Bravo B platform. Library pools were 
quantified using the KAPA Library Quantification Kit (#KK4824). Based on qPCR 
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quantification, libraries were then brought to 2 nM and denatured using 0.2N 
NaOH. After denaturation, libraries were diluted to 14-20 pM using Illumina 
hybridization buffer. Next, cluster amplification was performed on denatured 
templates according to manufacturer’s guidelines (Illumina), HiSeq v3 cluster 
chemistry and flow cells, as well as Illumina’s Multiplexing Sequencing Primer 
Kit. The pools were then added to flow cells using the cBot System and 
sequenced using the HiSeq 2000/2500 v3 Sequencing-by-Synthesis method, 
then analyzed using RTA v.1.13 or later. Each pool of whole exome libraries was 
subjected to paired 76 bp runs. An 8-base index-sequencing read was used to 
meet coverage and to demultiplex the pooled samples. Mean coverage for 
exome data was 177X in tumors and 91X in germline. Mean sequencing 
coverage and tumor purities were similar across groups, with the exception of on-
treatment biopsies given the presence of lower tumor content and enriched 
immune infiltrates. Therefore, whole exome sequencing data from on-treatment 
samples were excluded from downstream analysis. 
 
2.3.3 Mutation calling and intratumor heterogeneity analysis 
        Exome sequencing data was processed using SaturnV, the NGS data 
processing and analysis pipeline developed and maintained by the Bioinformatics 
group of the Institute for Applied Cancer Science and Department of Genomic 
Medicine at UT MD Anderson Cancer Center. BCL files (raw output of Illumina 
HiSeq) were processed using Illumina CASAVA (Consensus Assessment of 
Sequence and Variation) software (v1.8.2) for demultiplexing/conversion to 
	   27	  
FASTQ format. The FASTQ files were then aligned to the hg19 human genome 
build using BWA (v0.7.5) (67). The aligned BAM files were subjected to mark 
duplication, realignment, and recalibration using the Picard tool and GATK 
software tools (68-70). The BAM files were then used for downstream analysis. 
MuTect (v1.1.4) (71) was applied to identify somatic point mutations, and Pindel 
(v0.2.4) (72) was applied to identify small insertions and deletions. Somatic 
mutations in HLA genes were called by POLYSOLVER (v1.0) (32). EXPANDS 
(v1.6.1) (73) and SciClone (v1.0.7) (74) were applied with only LOH-free regions 
to estimate the number of clones per tumor. 
 
2.3.4 Neoantigen prediction 
        HLA class I neo-epitopes were predicted for each patient as previously 
described (75). In short, patient HLA-A, -B, and -C variants were identified using 
ATHLATES (v2014_04_26) (76). Next, all possible 9- to 11-mer peptides flanking 
a nonsynonymous exonic mutation were generated computationally, and binding 
affinity was predicted based on patient HLA and compared to that of the wild-type 
peptide counterpart using NetMHCpan (v2.8) algorithm (77). Mutated peptides 
with predicted IC50 < 500 nM were considered as predicted neoantigens. TCGA 
melanoma (78) gene expression data were used to further filter out predicted 
neoantigens with mean gene expression values below 5 (mean RSEM < 5). 
 
2.3.5 Copy number alteration analysis  
Sequenza (v2.1.2) (79) was applied to obtain copy number segments of 
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log2 copy ratios (tumor/normal) for each tumor sample. R package ‘CNTools’ 
(v1.24.0) (80) was used to identify copy number gain (log2 copy ratios > log21.5) 
or loss (log2 copy ratios < -log21.5) at the gene level. The burden of copy number 
gain or loss was then calculated as the total number of genes with copy number 
gain or loss per sample. For recurrent copy number alteration analysis, R 
package ‘cghMCR’ (v1.26.0) (81) was applied to log2 copy ratios (tumor/normal) 
obtained from ‘exomecn’ (in-house copy number caller). Segment Gain or Loss 
(SGOL) scores of copy number segments or genes were calculated as sum of 
log2 copy ratios of each copy number segment or gene across all samples within 
a group of interest. Copy number segments with both copy number gain and 
copy number loss present within a group were excluded. We identified genomic 
regions of recurrent copy number alterations (MCRs: minimum common regions) 
using cghMCR function with the following parameters: gapAllowed=500, 
alteredLow=-log2(1.5), alteredHigh=log2(1.5), recurrence=60, spanLimit=2e+07, 
thresholdType=”value” (recurrent copy number loss was defined as copy number 
loss observed in more than 60% of samples in a group of interest). Tumor 
suppressor genes annotated in recurrent copy number loss plots were obtained 
as cancer genes present in both the Catalogue of Somatic Mutations in Cancer 
(COSMIC) (v77) (82) and TSGene databases (83). Two samples were excluded 
from analysis due to unusable copy number profiles (45E and 20E).  
 
2.3.6 TCR sequencing and clonality analysis 
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        T cell receptor sequencing of the CDR3 variable region of the beta chain 
was performed by ImmunoSeq hsTCRB Kit as described previously (Adaptive 
Biotechnologies) (84, 85). In brief, DNA was extracted from FFPE tumor tissues, 
and CDR3 regions were amplified prior to sequencing by MiSeq 150X (Illumina). 
Data were then transferred to Adaptive Technologies for deconvolution of CDR3 
beta sequences. For each sample, Shannon entropy and TCR clonality were 
calculated using the ImmunoSeq Analyzer (86). 
 
2.3.7 NanoString gene expression profiling 
        NanoString was performed using a custom codeset of 795 genes as 
previously described (87). In brief, RNA was extracted using the RNeasy Mini Kit 
(QIAGEN) from FFPE blocks, after initial confirmation of tumor presence and 
content by two pathologists by H&E. For gene expression studies, 1 µg of RNA 
was used per sample. Hybridization was performed for 16-18 hours at 65°C, and 
samples were loaded onto the nCounter Prep Station for binding and washing 
prior to scanning and capture of 600 fields using the nCounter. Preprocessing of 
NanoString data was performed as previously described (87). Immune scores 
were calculated as geometric mean of gene expression of cytolytic markers 
(GZMA, GZMB, PRF1, GNLY), HLA molecules (HLA-A, HLA-B, HLA-C, HLA-E, 
HLA-F, HLA-G, HLA-H, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, 
HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1), IFN-γ 
pathway genes (IFNG, IFNGR1, IFNGR2, IRF1, STAT1, PSMB9), chemokines 
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(CCR5, CCL3, CCL4, CCL5, CXCL9, CXCL10, CXCL11), and adhesion 
molecules (ICAM1, ICAM2, ICAM3, ICAM4, ICAM5, VCAM1).  
 
2.3.8 Independent (Van Allen) cohort analysis 
        Mutational load was obtained from nonsynonymous mutational load in an 
earlier study (25). WES data (SAM files) from 110 melanoma patients and RNA-
seq data from 42 patients (FASTQ files) were downloaded through the dbGaP 
(accession number phs000452.v2.p1). Copy number alterations were identified 
from the same computational pipeline as described above. For the Van Allen 
cohort, recurrent copy number loss was defined as copy number loss observed in 
more than 40% of samples in a group of interest. Twelve samples were excluded 
from analysis due to unusable copy number profiles (Pat06, Pat73, Pat78, Pat81, 
Pat92, Pat106, Pat121, Pat132, Pat165, Pat166, Pat171, and Pat175). In the 
minimal or no clinical benefit group, samples with low burden of copy number 
loss (<100) were excluded from recurrent copy number alteration analysis. The 
relatively low cutoff of 100 was chosen to capture the majority of recurrent 
events. For RNA-seq analysis, all the RNA-seq samples were first aligned to the 
human reference genome (hg19, GRCh37.75) with Bowtie2 (v2.2.5). RSEM 
(v1.2.12) was used to quantify transcript expression at the gene level in FPKM. 
Immune scores for the independent cohort were calculated by ESTIMATE (88). 
eBayes-moderated t-test was performed to compare the high burden of copy 
number loss (n=10) and low burden of copy number loss groups (n=10). Rank 
metric was then calculated as the sign of log2 fold changes multiplied by inverse 
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of P values. Gene set enrichment analysis (GSEA) (89) was performed on the 
rank metric-sorted list of genes. 
 
2.3.9 Statistical analysis 
        Statistical analyses were performed using R 3.2.2. Statistical tests included 
two-sided Fisher’s exact tests and two-sided Mann-Whitney tests.  
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3.1 Introductions and Rationale 
        Major advances have been made in the treatment of metastatic melanoma 
through the use of immune checkpoint blockade, with the FDA approval of 
numerous therapeutic regimens within the past several years (21, 90-94) and 
many more being studied in clinical trials (95, 96). Treatment with immune 
checkpoint inhibitor monotherapy [such as monoclonal anti- bodies targeting 
cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) and programmed death-1 
(PD-1)] is associated with response rates of 8% to 44%, and many of these 
responses are durable (i.e., >2 years). However, the majority of patients do not 
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respond to these regimens as monotherapy, and some patients develop 
significant toxicity (90, 97-99), particularly when these regimens are combined 
(92). Given these complexities, a critical need exists to identify biomarkers that 
accurately predict which patients will benefit from this form of therapy. 
        Although several genomic and immune predictors of response have been 
reported based on analysis of pretreatment tumor biopsies, these biomarkers are 
not very robust, and there is significant overlap between responders and 
nonresponders to therapy for the markers tested (39, 41, 48, 100). Genomic and 
RNA-based studies exploring predictors of outcome to immune checkpoint 
blockade in melanoma suggest that tumor-specific mutational load and 
neoantigen signature as well as cytolytic activity are significantly associated with 
clinical benefit and increased overall survival (25, 39, 101). IHC-based studies 
also support the notion that CD8+, CD4+, PD-1+, and programmed death-ligand 
1–positive (PD-L1+) cell densities in pretreatment biopsies can predict response 
to therapy (48, 100). However, cumulative evidence from these studies suggests 
that these biomarkers are not perfectly predictive (39, 48), and better biomarkers 
are clearly needed to optimize therapeutic decisions. 
        In addition to identifying predictors of response to immune checkpoint 
blockade, there is growing interest in understanding the mechanistic differences 
between different forms of immune checkpoint blockade. Transcriptome and 
pathway analysis using purified human T cells and monocytes from patients on 
either CTLA4 or PD-1 blockade demonstrates distinct gene expression profile 
and immunologic effects between these forms of therapy (102, 103). Whereas 
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CTLA4 blockade induces a proliferative signature in memory T cells, PD-1 
blockade leads to changes in genes implicated in cytolysis and natural killer cell 
function (103). This notion is further supported by animal models that 
demonstrate differential effects of CTLA4 and PD-1 blockade therapies on the 
transcriptional profiles of tumor-infiltrating CD8+ T cells, with increased NFAT–
JAK–STAT signaling, cell proliferation/cell cycle, and activation of effector T-cell 
pathways seen in CTLA4 blockade versus changes in IL2 signaling, response to 
type I IFN, and metabolic pathways seen in PD-1 blockade (102). 
        Along with this, there is a critical need to identify mechanisms of therapeutic 
resistance to immune checkpoint inhibitors that are potentially actionable. Groups 
have begun to study this (50, 101), and there is evidence that somatic mutations 
in antigen processing and presentation as well as upregulation of genes involved 
in cell adhesion, angiogenesis, and extracellular matrix remodeling may 
contribute to immune escape in cancer (104). In addition, molecular analyses of 
human melanoma samples and animal models also suggest that tumor-intrinsic 
oncogenic signals related to the WNT/β-catenin signaling pathway may mediate 
cancer immune evasion and resistance to immunotherapy, including CTLA4- and 
PD-1–based therapy (105). 
        In this study, we sought to address each of these areas of critical need by 
studying a unique cohort of patients with metastatic melanoma who were initially 
treated with CTLA4 blockade and were then treated with PD-1 blockade at time 
of progression. A deep immune analysis of longitudinal tumor samples was 
performed, yielding insights into biomarkers of response, mechanistic differences 
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between each of these forms of therapy, and means of therapeutic resistance to 
immune checkpoint blockade. 
 
3.2 Results 
3.2.1 Patient Cohort, Checkpoint Blockade Treatment, and Longitudinal 
Tumor Biopsies 
        To explore differential changes in the tumor microenvironment in distinct 
forms of immune checkpoint blockade, we assembled a unique cohort of 53 
patients with metastatic melanoma who were initially treated with CTLA4 
blockade and were then treated with PD-1 blockade if they did not respond or 
progressed on therapy. The scheme of treatment and longitudinal tumor 
sampling is shown in Figure 1. Biopsies were obtained (when available) prior to 
initiation of CTLA4 blockade, on-treatment, and after restaging in patients who 
did not respond to or who progressed on therapy. Clinical responders were 
defined by radiographic evidence of absent disease, stable disease, or 
decreased tumor volume for >6 months. Nonresponders were defined by tumor 
growth on serial CT scans after the initiation of treatment or any clinical benefit 
lasting ≤6 months (minimal benefit). Nonresponders to CTLA4 blockade were 
then treated with PD-1 blockade therapy, and additional biopsies were obtained 
early during the course of therapy and late on-treatment in nonresponders (or 
progressors) on PD-1 blockade (Figure 1). Among the patients treated with 
CTLA4 blockade, 13% achieved clinical benefit, whereas 87% did not, consistent 
with published response rates (21, 99). Table 1 and 2 shows the clinical and 
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demographic characteristics of the patients in this cohort. Available biopsies were 
subsequently processed for downstream immune profiling by IHC and gene 
expression studies (Table 3 and 4).        
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Figure 1. A cohort of patients treated with sequential CTLA4 and PD-1 blockade. 
Patients with metastatic melanoma were initially treated with CTLA4 blockade (n = 53) 
and nonresponders to CTLA4 blockade were then treated with PD-1 blockade (n = 46; 
Expanded Access Program for MK-3475 at the MD Anderson Cancer Center). Of these 
46 patients, 13 responded to PD-1 blockade, whereas 33 progressed. Tumor biopsy 
samples were collected at multiple time points during their treatment when feasible, 
including pretreatment, on-treatment, and progression anti–CTLA4 biopsies, and 
pretreatment, on-treatment (doses 2–3), and progression anti–PD-1 biopsies, for 
downstream immune profiling by IHC and gene expression studies. The median elapsed 
time between tumor biopsies and treatment is shown for each time point. The profile and 
kinetics of immune cell infiltrates in the tumor microenvironment were compared 
between responders and nonresponders to CTLA4 blockade. Tumor samples available 
for immune profiling by IHC included pretreatment anti-CTLA4 [n = 36; 5 responders (R) 
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and 31 nonresponders (NR)], on-treatment anti-CTLA4 (n = 5; 2 responders and 3 
nonresponders) and progression anti-CTLA4 biopsies (n = 22). 
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Anti%CTLA%4*Responders Anti%PD%1*Responders Anti%PD%1*Progressors All*Patients*
(n=7) (n=15) (n=33) (n=56)
Age*at*start*of*first*immunotherapy
Mean- 61 57 56 57
Range 47182 27186 28184 27186
Sex%*no.*of*patients*(%)
Female 5-(71) 4-(27) 10-(30) 19-(34)
Male 2-(29) 11-(73) 23-(70) 37-(66)
Disease*Origin%*no.*of*patients*(%)
Acral 1-(14) 2-(13) 4-(12) 7-(12)
Cutaneous 5-(71) 9-(60) 24-(73) 39-(70)
Mucousal 0-(0) 1-(6) 0-(0) 1-(2)
Unknown-Primary 1-(14) 3-(20) 5-(15) 9-(16)
Mutational*Status%*no.*of*patients*(%)
BRAF 4-(50) 4-(22) 2-(7) 10-(22)
NRAS 1-(12) 5-(28) 10-(34) 16-(29)
CKIT 0 1-(5) 4-(14) 5-(9)
TP53 2-(25) 2-(11) 5-(26) 9-(16)
Lactate*dehydrogenase*level*at*start*of
therapy*—*no.*of*patients*(%)
Normal-(<618-IU/L) 2-(29) 11-(74) 1-(3) 15-(27)
Above-Normal-(>-618-IU/L) 4-(57) 2-(13) 25-(76) 31-(55)
Not-Available 1-(14) 2-(13) 7-(21) 10-(18)
Previous*Therapies*%no.*
Mean- 1 2 4 2
Range 014 017 019 019
Duration*between*aCTLA%4*and*aPD1%%wk
Mean NA 21.6 36.7 NA
Range- NA 0186 01165 NA
RECIST*Response*Classification*
Progression-of-Disease 2-(29) 3-(20) 33-(100) 38-(68)
Stable-Disease 0-(0) 3-(20) 0-(0) 3-(5)
Partial-Response 5-(71) 7-(47) 0-(0) 12-(21)
Complete-Response 0-(0) 2-(13) 0-(0) 2-(4)
* includes 1 additional patient (Patient 17) who progressed on anti-CTLA-4 and did not receive anti-PD-1 
 
Table 1. Cohort level clinical summary 
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Patient'
ID
Group'
(1=IR,2=INR,3=PDR,4=
PDNR)
Sex' Age
anti=CTLA=4'
Response
anti=PD=1'
Response
Treated'
(Y/N)
RECIST'(CR,'
PR,'SD,'PD)
#'of'prior'or'
concurrent'therapies
Treated'
(Y/N)
RECIST'(CR,'
PR,'SD,'PD)
#'of'prior'or'
concurrent'therapies
1 4 F 48 nonresponse nonresponse Y PD 1 Y PD 3
2 4 M 50 nonresponse nonresponse Y PD 2 Y PD 3
3 4 F 60 nonresponse nonresponse Y PD 3 Y PD 4
4 4 M 72 nonresponse nonresponse Y PD 4 Y PD 8
5 1 F 47 response NA Y PR 3 N NA NA
6 3 M 48 nonresponse response Y PD 1 Y PD* 2
7 3 M 64 nonresponse response Y PD 1 Y PR 2
8 3 M 54 nonresponse response Y PD 1 Y CR 2
9 3 M 58 nonresponse response Y PD 2 Y SD 4
10 1 F 54 response NA Y PR 0 N NA NA
11 4 M 82 nonresponse nonresponse Y PD 3 Y PD 5
12 1 M 70 response NA Y PD* 2 N NA NA
13 4 M 52 nonresponse nonresponse Y PD 0 Y PD 2
14 3 F 66 nonresponse response Y PD 1 Y PR 2
15 3 F 43 NA response N NA NA Y PD* 0
16 4 M 34 nonresponse nonresponse Y PD 0 Y PD 2
17 2 F 58 nonresponse NA Y PD 0 N NA NA
18 4 F 66 nonresponse nonresponse Y PD 2 Y PD 3
19 4 M 55 nonresponse nonresponse Y PD 3 Y PD 8
20 4 M 59 nonresponse nonresponse Y PD 1 Y PD 2
21 4 M 63 nonresponse nonresponse Y PD 0 Y PD 1
22 1 F 50 response NA Y PR 0 N NA NA
23 4 M 40 nonresponse nonresponse Y PD 0 Y PD 1
24 3 M 50 nonresponse response Y PD 0 Y SD 2
25 4 F 46 nonresponse nonresponse Y PD 4 Y PD 6
26 4 F 60 nonresponse nonresponse Y PD 1 Y PD 7
27 1 F 56 response NA Y PR 0 N NA NA
28 4 M 55 nonresponse nonresponse Y PD 2 Y PD 4
29 4 M 34 nonresponse nonresponse Y PD 7 Y PD 9
30 4 M 66 nonresponse nonresponse Y PD 1 Y PD 2
31 1 F 71 response NA Y PD* 4 N NA NA
32 4 F 84 nonresponse nonresponse Y PD 0 Y PD 1
33 4 F 61 nonresponse nonresponse Y PD 0 Y PD 2
34 3 M 69 nonresponse response Y PD 1 Y PR 2
35 3 F 49 nonresponse response Y PD 0 Y CR 1
36 4 M 56 nonresponse nonresponse Y PD 1 Y PD 4
37 1 M 82 response NA Y PR 1 N NA NA
38 4 F 53 nonresponse nonresponse Y PD 0 Y PD 2
39 4 M 55 nonresponse nonresponse Y PD 1 Y PD 4
40 4 M 53 nonresponse nonresponse Y PD 1 Y PD 5
41 4 M 68 nonresponse nonresponse Y PD 3 Y PD 6
42 4 F 48 nonresponse nonresponse Y PD 2 Y PD 6
43 4 M 61 nonresponse nonresponse Y PD 2 Y PD 2
44 4 F 62 nonresponse nonresponse Y PD 0 Y PD 1
45 4 M 59 nonresponse nonresponse Y PD 0 Y PD 5
46 3 F 27 nonresponse response Y PD 3 Y PR 4
47 3 M 72 nonresponse response Y PD 2 Y PR 3
48 4 M 68 nonresponse nonresponse Y PD 2 Y PD 3
49 4 M 46 nonresponse nonresponse Y PD 1 Y PD 4
50 4 M 68 nonresponse nonresponse Y PD 0 Y PD 4
51 3 M 37 nonresponse response Y PD 1 Y PD* 2
52 3 M 65 nonresponse response Y PD 5 Y SD 7
53 4 M 54 nonresponse nonresponse Y PD 5 Y PD 6
54 4 M 28 nonresponse nonresponse Y PD 2 Y PD 3
55 3 M 86 NA response N NA NA Y PR 0
56 3 M 69 nonresponse response Y PD 1 Y PR 2
anti?CTLA?4 anti=PD=1
 
Table 2. Patient level clinical characteristics 
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Pre On Pro Pre On Pro
1 No$sample$profiled
2 Sample$profiled
3 Not$applicable
4
5
6
7
8
10
12
13
14
•15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
38
39
40
41
42
43
44
45
47
49
50
51
52
53
54
•55
•56
•58
•59
•60
•61
•63
•64
•65
•67
•68
•=$CTLAB4$blockade$naïve$patients
antiBCTLAB4 antiBPDB1
Patient*ID
 
Table 3. Immune profiling by IHC sample log 
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Pre On Pro Pre On Pro
1 No$sample$profiled
2 Sample$profiled
3 Not$available
4
5
6
7
8
9
10
•15
16
18
19
22
23
24
25
26
27
31
37
40
42
43
45
47
49
50
52
54
•=$CTLAB4$blockade$naïve$patients
Patient*ID
antiBCTLAB4 antiBPDB1
 
Table 4. Immune profiling by NanoString 54 sample log 
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3.2.2 Immune Profiling in Early On-Treatment Biopsies Is Predictive of 
Response to CTLA4 Blockade in a Unique Cohort of Patients Treated with 
Sequential CTLA4 and PD-1 Blockade 
        The profile and kinetics of immune cell infiltrates in the tumor 
microenvironment were first investigated via a 12-marker IHC panel. At the 
pretreatment time point, there was no difference in any of the measured markers 
between responders versus nonresponders to CTLA4 blockade (Figure 2), 
consistent with previous reports (106). However, analysis of early on-treatment 
tumor biopsies identified a significantly higher density of CD8+ T cells in 
responders versus nonresponders to CTLA4 blockade (Figure 2; P < 0.05). IHC 
for other immune and immunomodulatory markers at the on-treatment time point 
on CTLA4 blockade showed no significant differences in responders versus 
nonresponders, though a trend toward higher PD-L1 expression was observed in 
responders (Figure 2). Representative IHC images for CD8, CD4, and PD-L1 
expression in responders and nonresponders to CTLA4 blockade are shown for 
each time point in Figure 3. 
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Figure 2. Immune profiling of pre-treatment, on-treatment and progression CTLA-4 
blockade samples by immunohistochemistry. Immune profiling was performed via a 
12-marker immunohistochemistry panel. CD8, CD4, PD-L1 (H-score), CD45RO, CD3, 
CD20, CD57, CD68, FoxP3, Granzyme B, PD-1, and LAG-3 were assessed for density 
by quantitative IHC. Error bars represent standard error mean. n.s.= not significant 
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(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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Figure 3. Representative IHC images of CD8, CD4, and PD-L1 in responders and 
nonresponders at the pre- and on-treatment time point. Representative images at 
pretreatment and early on-treatment time points are shown in responders versus 
nonresponders to CTLA4 blockade (20× magnification). Error bars, SEM. *, P ≤ 0.05; 
n.s., not significant. Scale bars, 200 µm. 
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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        In addition, to better understand the contribution of myeloid–T cell 
interactions to therapeutic response, we also stained sections with additional 
myeloid markers (CD14, CD33, CD163, and CD206). Though we saw no clear 
quantitative differences in any of the myeloid subsets in responders versus 
nonresponders to CTLA4 blockade (Figure 4), we observed a slightly higher 
proximity of CD68+ myeloid cells to CD8+ T cells in nonresponders at the 
pretreatment time point (Figure 5A and 5B; P = 0.08); however, this did not reach 
statistical significance in this small cohort. 
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Figure 4. Myeloid cell profiling of pre-treatment, on-treatment and progression 
CTLA-4 blockade samples by immunohistochemistry. Immune profiling was 
performed via a 4-marker immunohistochemistry panel. CD14 (a), CD33 (b), CD163 (c), 
and CD206 (d) were assessed for density by quantitative IHC. Shown in (e)-(h) are 
representative IHC images in responders and non-responders at the pre-treatment 
timepoint. Error bars represent standard error mean. n.s.= not significant. Statistical 
analysis was not possible between responders and non-responders at on-treatment time 
point as only one sample was available per group. 
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
 
 
 
 
	   51	  
 
 
Figure 5. Increased contact between CD8 T cells and CD68 myeloid cells in non-
responding patients to anti-CTLA-4 and anti-PD-1 therapy at pre-treatment CTLA-4 
blockade, pre-treatment PD-1 blockade, and on-treatment PD-1 blockade time 
points. (a) Immunofluorescence staining showing nuclei by DAPI (blue), CD8 (red) and 
CD68 (yellow) cells in a responder and non-responder. (b) Semi-quantitative 
pathological assessment of percentage of CD8 and CD68 cells in contact in responders 
and non-responders pre-treatment and on treatment with anti-CTLA-4 and anti-PD-1 
therapy.  
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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3.2.3 Immune Profiling in Early On-Treatment Biopsies Is Highly Predictive 
of Response to PD-1 Blockade 
        We next used our 12-marker IHC panel to interrogate the profiles and 
kinetics of immune cell subsets in tumor samples from patients on anti–PD-1 
therapy. Forty-six patients were included who were initially treated with CTLA4 
blockade, as well as 11 additional patients who had not received prior CTLA4 
blockade to control for possible prior CTLA4 blockade exposure effects. In these 
studies, we observed a modest but statistically significant difference in the 
density of CD8+, CD3+, and CD45RO+ T cells in pretreatment samples of 
responders compared with nonresponders (Figure 6; P = 0.03, 0.03, 0.02, 
respectively), though the values between these two groups were largely 
overlapping, consistent with prior published data (106). There was also a trend 
toward higher pretreatment expression of CD4 and PD-1 in responders versus 
nonresponders, though these did not reach statistical significance (Figure 6; P = 
0.06, P = 0.08, respectively). 
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Figure 6. Immune profiling of pre-treatment, on-treatment and progression PD-1 
blockade samples by immunohistochemistry. Longitudinal tumor biopsies were per- 
formed (at pretreatment, early on-treatment, and late on-treatment/progression time 
points) in patients undergoing treatment with PD-1 blockade (n = 47). The profile and 
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kinetics of immune cell infiltrates in the tumor microenvironment were compared 
between responders (R) and nonresponders (NR) to PD-1 blockade. Tumor samples 
available for immune profiling by IHC included pretreatment anti–PD-1 (n = 24; 7 
responders and 17 nonresponders), on-treatment anti–PD-1 (doses 2–3; n = 11; 5 
responders and 6 nonresponders), and progression anti–PD-1 (n = 12) biopsies. CD8, 
CD4, CD3, PD-1, PD-L1 (H-score), LAG3, CD45RO, CD20, CD57, CD68, FoxP3, and 
Granzyme B density are shown in responders versus nonresponders. 
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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        In contrast, there was a profound and highly statistically significant 
difference in the expression of markers for T-cell subsets—CD8 (P = 0.001), CD4 
(P = 0.001), and CD3 (P < 0.001)— and immunomodulatory molecules PD-1 (P < 
0.001), PD-L1 (P = 0.007), and LAG3 (P < 0.0001) in responders versus non- 
responders to therapy in early on-treatment tumor samples, with little to no 
overlap between groups (Figure 6). Of note, a significantly higher level of 
expression of FOXP3 (P < 0.001) and granzyme B (P = 0.02) was observed in 
responders compared with nonresponders to therapy, likely relating to an 
enhanced activation status of infiltrating T cells in responding patients (Figure 6). 
Importantly, these changes were observed in responders as early as 2 to 3 
doses following initiation of PD-1–based therapy. Representative IHC images for 
these markers are shown in Figure 7. Specific analysis performed on longitudinal 
samples also demonstrated an increase in CD8, PD-1, and PD-L1 in responders 
compared with nonresponders to PD-1–based therapy (Figure 8). 
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Figure 7. Representative immunohistochemistry images of selected markers at 
pretreatment and early on-treatment time points. Representative images at 
pretreatment and early on-treatment time points are shown in responders versus 
nonresponders to PD-1 blockade (20× magnification). Error bars, SEM. *, P ≤ 0.05; **, P 
≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; n.s., not significant. Scale bars, 200 µm. 
(The experiment was done by Dr. Pei-Ling Chen. This figure was used with permission 
from Dr. Pei-Ling Chen.) 
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Figure 8. Longitudinal increase in CD8, PD-1, and PD-L1 expression in responders 
to anti-PD-1 therapy. Five paired responder (a, c, e) and 14 paired non-responder (b, 
d, f) samples were evaluated for changes in CD8 (a-b) and PD-1 (c-d) counts/mm2 and 
PD-L1 (e-f) H-Score at pre/on-treatment and on/post-treatment time points by 
immunohistochemistry. Lines link paired samples.  
(The analysis was done by Dr. Pei-Ling Chen. This figure was used with permission from 
Dr. Pei-Ling Chen.) 
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        In light of previous studies demonstrating the importance of the invasive 
tumor margin in predicting responses to PD-1 blockade (48), we quantified CD8+ 
T-cell density at the tumor margin in 41 samples with discernible tumor margins. 
In these studies, we did not observe significant differences in CD8+ T cells at the 
tumor margin between responders and non- responders to PD-1–based therapy 
at all time points examined, though sample size was admittedly limited. However, 
when we compared the ratio of CD8+ T cells at tumor center versus the margin in 
early on-treatment biopsies, we observed significantly higher ratios of CD8+ T 
cells at the tumor center versus the margin within responders compared with 
nonresponders (Figure 9A–9H), suggesting possible infiltrate from margin to 
center of the tumor in the context of therapy. 
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Figure 9. Relative increase in CD8 T cell infiltrate at tumor center in responders to 
anti-PD-1 on treatment. Pie charts depicting the CD8 counts/mm2 at pre-treatment 
anti-CTLA-4 (a-b), pre-treatment anti-PD-1 (c, d), and on treatment anti-PD-1 (e, f) time 
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points in responders and non-responders at tumor margin (g) and center (h). Numbers 
represent average counts per treatment time point. Blue = Tumor margin, Red = Tumor 
center. Pre-treatment anti-CTLA-4: Responders (n=3), Non-responders (n=15); Pre-
treatment anti-PD-1: Responders (n=2), Non-responders (n=8); On treatment anti-PD-1: 
Responders (n=2), Non-responders (n=2).  
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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        To augment these studies, we performed immune profiling in the separate 
cohort of patients who received PD-1 blockade in the absence of prior CTLA4 
exposure, and observed no significant differences in our prior observations when 
these patients were included in the analysis (Figure 10A–10H). As observed 
previously with CTLA4 blockade, we saw no clear quantitative difference in any 
of the myeloid subsets in responders and nonresponders to PD-1 blockade 
(Figure 11A–11I). However, we observed a significantly higher proximity of 
CD68+ myeloid cells to CD8+ T cells in nonresponders at the pretreatment and 
on-treatment time points for patients on PD-1 blockade (Figure 5, P < 0.05). 
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Figure 10. Significant increase in immune infiltrate between responders and non-
responders to PD-1 blockade in absence of prior anti-CTLA-4 therapy. (a) Timeline 
illustrating breakdown of anti-CTLA-4-naïve patient samples by response and treatment 
time point and planned analyses. CD4 (b), CD8 (c), FoxP3 (d), GzmB (e), PD-1 (f), PD-
L1 (g), and LAG-3 (h) were assessed for density by quantitative IHC. Error bars 
represent standard error mean. n.s.= not significant. Black dots depict anti-CTLA-4-naïve 
patients. *= p≤0.05, **= p≤0.01, ***= p≤0.001, n.s.= not significant.  
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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Figure 11. Immune profiling of myeloid cells atpre-treatment and on-treatment PD-
1 blockade time points by immunohistochemistry. CD14 (a), CD33 (b), CD163 (c), 
and CD206 (d) were assessed for density by quantitative IHC. Shown in (e-h) and (i-l) 
are representative IHC images in responders and non-responders at the pre-treatment 
and on treatment timepoints, respectively. Error bars represent standard error mean. 
n.s.= not significant.  
(The experiment and analysis were done by Dr. Pei-Ling Chen. This figure was used 
with permission from Dr. Pei-Ling Chen.) 
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3.2.4 Gene Expression Profiling in Longitudinal Tumor Biopsies Is 
Predictive of Response in Patients Treated with Sequential CTLA4 and PD-
1 Blockade 
        To further dissect the tumor microenvironment–mediated response and 
resistance to immune checkpoint blockade and to identify potential mechanisms 
of therapeutic resistance, we performed targeted gene expression profiling (GEP) 
via a custom 795-gene NanoString panel composed of immune-related genes 
and genes pertaining to common cancer signaling pathways in samples with 
available tissue. When comparing GEP results between responders and non- 
responders at each individual biopsy time point, no significant differences were 
found at pretreatment CTLA4 blockade, on- treatment CTLA4 blockade, and 
pretreatment PD-1 blockade. However, early on-treatment tumor samples of 
patients on anti– PD-1 therapy showed 411 significantly differentially expressed 
genes (DEG) in responders (FDR-adjusted P < 0.05), mostly upregulated as 
compared with nonresponders (Figure 12A–D and Figure 13), including IHC 
markers represented in the NanoString code- set, cytolytic markers, HLA 
molecules, IFNγ pathway effectors, chemokines and select adhesion molecules. 
Notably, a small number of DEGs (n = 6) were lower in responders than in non- 
responders on PD-1 blockade and included vascular endothelial growth factor 
(VEGFA), suggesting a mechanism of therapeutic resistance and a potential 
target for therapy, which is corroborated by data from others implicating 
angiogenesis in resistance to immunotherapy (107-109). Notably, though only 10 
of the 12 IHC markers were represented in the NanoString codeset, all 10 
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overlapping probes showed concordance with our IHC findings (Figure 14A–14J 
and Figure 15). 
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Figure 12.  Gene expression profiling in longitudinal tumor biopsies is predictive 
of response in a unique cohort of patients treated with sequential CTLA4 and PD-1 
blockade. Gene expression profiling was performed via NanoString in longitudinal tumor 
biopsies from patients treated with sequential CTLA4 and PD-1 blockade (n = 54), 
including pretreatment anti–CTLA4 [n = 16; 5 responders (R) and 11 nonresponders 
(NR)], on-treatment anti-CTLA4 (n = 5; 3 responders and 2 nonresponders), and 
progression anti–CTLA4 biopsies (n = 15), pretreatment anti–PD-1 (n = 16; 7 responders 
and 9 nonresponders), on-treatment anti–PD-1 (doses 2–3; n = 10; 5 responders and 5 
nonresponders), and progression anti–PD-1 (n = 7) biopsies. Volcano plots illustrate the 
log2 fold change (FC) in gene expression (responders vs. nonresponders) on the x-axis 
and unadjusted P values from Student t tests between responders and nonresponders 
on the y-axis. Differentially expressed genes (FDR-adjusted P < 0.05 and FC >2 or 
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<−1/2) between responders and nonresponders were highlighted in green at the time of 
pretreatment (A) and on-treatment (B) CTLA4 blockade, pretreatment (C) and on-
treatment (D) PD-1 blockade. Interaction of time covariate (pretreatment, on-treatment) 
and response covariate (responders, nonresponders) was illustrated in volcano plots. 
Genes with significant interaction were highlighted in green (FDR-adjusted P < 0.05 and 
interaction >1.5 or <−1.5) for CTLA4 blockade (E) and PD-1 blockade (F). Venn diagram 
illustrates shared and unique genes upregulated and downregulated in CTLA4 (red) and 
PD-1 (blue) blockade over treatment time course (G).  
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Figure 13. Heatmap of 54 NanoString samples. Values are log2-transformed 
normalized mRNA count. Samples are ordered by treatment time point and by 
responsiveness to anti-CTLA-4 or anti-PD-1 therapy. Color pattern is relative with 
respect to the row within each time point, with red indicating gene up-regulation and 
green indicating gene down-regulation. 
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Figure 14. Gene-specific NanoString concordance with immune profiling by IHC in 
pre-treatment, on-treatment and progression CTLA-4 blockade samples. Gene 
expression profiling was performed via NanoString on 54 tumor biopsies. Of the custom-
designed 795 probe code set, 10 probes were represented in our immune profiling 
analysis by IHC, namely CD3, CD4, CD8, CD45RO, CD68, FoxP3, Granzyme B, LAG-3, 
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PD-1 and PD-L1. All values represented by box and whisker plots. *= p≤0.05, **= 
p≤0.01, ***= p≤0.001, n.s.= not significant.  
(The analysis was done by Dr. Pei-Ling Chen. This figure was used with permission from 
Dr. Pei-Ling Chen.) 
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Figure 15. Gene-specific NanoString concordance with immune profiling by IHC in 
pre-treatment, on-treatment and progression PD-1 blockade samples. Gene 
expression profiling was performed via NanoString on 54 tumor biopsies. Of the custom-
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designed 795 probe code set, 10 probes were represented in our immune profiling 
analysis by IHC, namely CD3, CD4, CD8, CD45RO, CD68, FoxP3, Granzyme B, LAG-3, 
PD-1 and PD-L1. All values represented by box and whisker plots. 
*= p≤0.05, **= p≤0.01, ***= p≤0.001, n.s.= not significant.  
(The analysis was done by Dr. Pei-Ling Chen. This figure was used with permission from 
Dr. Pei-Ling Chen.) 
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        We next compared GEPs between pretreatment and on- treatment time 
points to identify dynamic changes in the tumor microenvironment associated 
with each form of immune checkpoint therapy. To do this, I used the linear 
mixed-effects model to test time trend of gene expression from pretreatment to 
on-treatment and its interaction with response status for CTLA4 and PD-1 
blockade, respectively. With CTLA4 blockade, 173 upregulated DEGs and 101 
downregulated DEGs were identified in responders versus nonresponders to 
therapy (Figure 12E), with upregulated DEGs similar to those described in 
previously published datasets (102). With PD-1 blockade, 370 upregulated DEGs 
and 6 downregulated DEGs were identified in responders versus nonresponders 
(Figure 12F). Upregulated DEGs related to processes such as antigen 
presentation, T-cell activation, and T-cell homing. Importantly, we did not observe 
significant differences in GEPs in PD-1–treated patients regardless of prior 
treatment with CTLA4 blockade (Figure 16); however, the cohort was admittedly 
small and we cannot exclude the possibility that these GEPs may in part be due 
to prior treatment with CTLA4 blockade. 
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Figure 16. Prior CTLA-4 blockade is not required for PD-1 early on-treatment 
profile. Heatmap of 28 anti-PD-1 samples, which included 7 pre-treatment samples (4 
responders, 3 non-responders) and 8 on-treatment samples (3 responders, 5 non-
responders) with prior CTLA-4 exposure, as well as 8 pre-treatment samples (6 
responders, 2 non-responders) and 5 on-treatment samples (2 responders and 3 non-
responders) that were CTLA-4 blockade-naïve. Values are median-centered and log2-
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transformed. Hierarchical clustering was performed on gene expression (higher 
expression in dark blue, lower expression in light blue).  
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        To investigate mechanistic differences between the two forms of immune 
checkpoint blockade, we next compared the response-associated DEGs (from 
pretreatment to on-treatment) in tumor biopsies of CTLA4- versus PD-1–treated 
patients. In this comparison, only 117 shared DEGs were upregulated for both 
CTLA4 and PD-1 blockade (Figure 12G), with 56 upregulated DEGs unique to 
CTLA4 blockade, and 253 unique to PD-1 blockade (FDR-adjusted P < 0.05). 
Analysis of shared downregulated DEGs revealed 99 that were unique to CTLA4 
blockade and 4 that were unique to PD-1 blockade (FDR-adjusted P < 0.05), with 
only two common DEGs in responders versus non- responders across both 
forms of therapy, including dual serine/threonine and tyrosine protein kinase 
(DSTYK) and S100 Calcium Binding Protein A1 (S100A1). 
 
3.3 Discussion 
        Immune checkpoint blockade therapies have revolutionized the treatment of 
advanced melanoma and other cancer types; however, only a fraction of patients 
benefit from these treatments as monotherapy, and robust predictors of response 
and mechanisms of therapeutic resistance are currently lacking. Though data 
suggest a correlation among clinical response, preexisting tumor-infiltrating 
lymphocytes, T-cell repertoire, tumor-intrinsic mutational load, and neoantigens, 
the demonstrated biomarker profiles between responders and nonresponders are 
often overlapping and not very robust (97, 100). 
        Together, the studies presented herein build on collective efforts to identify 
biomarkers of response and resistance to immune checkpoint blockade (39, 48, 
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100), and provide novel evidence that assessment of adaptive immune 
responses early in the course of therapy is highly predictive of response—with 
nonoverlapping immune signatures in responders versus nonresponders, 
particularly to PD-1 blockade. These data have important clinical implications and 
suggest that immune signatures in tumor biopsies should be evaluated early after 
initiation of treatment with immune checkpoint blockade rather than in 
pretreatment tumor samples—at least until better predictive markers in 
pretreatment tissue and blood samples may be identified. This is highly relevant, 
as many clinical trials of immune checkpoint inhibitors currently mandate 
assessment of immune markers only in pretreatment tumor tissue; however, our 
findings suggest that we should reconsider this approach and assess adaptive 
immune responses in patients on therapy. Of note, we recognize the immune 
signatures observed in early on-treatment samples may simply be a 
consequence of the immune response to checkpoint inhibitors, and may not 
represent bona fide mechanisms of therapeutic response. Additional studies are 
needed to fully delineate whether these immune signatures are responsible for, 
or a product of, the mechanisms underlying the response—though are admittedly 
out of the context of the current study. Importantly, similar observations have 
been made in other tumor types (110), suggesting that such an approach could 
be applicable to other solid tumors—though this hypothesis needs to be tested 
more broadly. 
        These data also offer mechanistic insight into response to immune 
checkpoint blockade, suggesting that response to PD-1 blockade is related to 
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enhanced cytolytic activity, antigen processing, and IFNγ pathway components 
(25, 101). Interestingly, VEGFA was decreased in responders and increased in 
nonresponders to therapy, suggesting a mechanism of therapeutic resistance as 
observed by others (107-109) and a potential target for therapy. The 
antiangiogenesis pathway has been shown to interact with antitumor immunity 
through multiple mechanisms. Previous studies demonstrate that increased 
VEGF secretion decreases T-cell effector function and trafficking to tumor (111, 
112) and correlates with increased PD-1 expression on CD8 T cells (108). In 
addition to direct effect on T cells, VEGF also decreases the number of immature 
dendritic cells as well as T-cell priming ability of mature dendritic cells (113), 
further contributing to decreased effector T-cell function. Angiogenic factors have 
also been shown to expand T regulatory cell (114) and myeloid-derived 
suppressor cell populations. Based on these findings and preclinical and 
translational data supporting synergy between angiogenesis inhibitors and 
immunotherapies, multiple trials of combination therapy are under way, including 
bevacizumab with anti–PD-1 therapy (109). Phase I trial data from patients with 
advanced melanoma of bevacizumab and ipilimumab support synergy with this 
combination therapy, showing a 67% disease control rate, increased CD8 T-cell 
tumor infiltration, and circulating memory CD4 and CD8 T cells with combination 
therapy (109, 115). Our data are in line with these studies and reinforce the value 
in these combination anti-VEGF/anti–PD-1 clinical trials. 
        In addition, these data provide strong evidence regarding differential effects 
of distinct forms of immune checkpoint blockade on the tumor microenvironment, 
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with insight into distinct mechanisms of response and of therapeutic resistance, 
which is in line with prior published reports in mice (102) and in humans (103). 
These differences have important clinical implications and may help guide 
rational therapeutic combinations of distinct immune checkpoint inhibitors and 
immunomodulatory agents depending on the desired treatment effect. 
        An important consideration is that the differences in immune infiltrates 
observed in responders versus nonresponders to PD-1–based therapy could be 
related to prior treatment with CTLA4 blockade, though gene expression 
analyses and IHC results in CTLA4-naïve versus CTLA4-experienced patients 
did not differ significantly. This cohort is admittedly small and results need to be 
validated in larger cohorts and in other histologies. Based on available data from 
this and other groups, biopsies should be performed early on treatment (i.e., 
within 2 to 3 cycles of therapy) to validate these studies. In addition, though these 
novel findings are provocative, they may be difficult to validate in other solid 
tumor types where acquisition of early on-treatment biopsies may be less 
feasible. Nonetheless, there is a critical need to study this phenomenon in other 
solid tumors, as results from such studies may help usher in a new paradigm for 
immune monitoring in the setting of immune checkpoint blockade—with 
emphasis placed on assessment of an adaptive immune response in an early on- 
treatment biopsy rather than in pretreatment markers. 
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Chapter 4 GENOMIC PROFILING  
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4.1 Introductions and Rationale 
        Immune checkpoint blockade represents a major advancement in cancer 
therapy for advanced melanoma. However, durable clinical responses are seen 
in only a minority of patients treated with single-agent CTLA-4 (116) or PD-1 
blockade (116, 117). Although higher response rates are achieved when CTLA-4 
and PD-1 inhibitors are administered concurrently, this regimen also has greatly 
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increased toxicity (116, 118). There is a clinical need to predict who will benefit 
from immunotherapy and to understand mechanisms of therapeutic resistance to 
improve patient management and outcomes. Recently, evidence has pointed to a 
role of tumor molecular features (such as mutational load) (25, 41, 75, 119) and 
host immune infiltrates (40, 59, 86, 120) in response to therapy, though 
complexities exist with the predictive power of these markers (121). Studies have 
also begun to uncover mechanisms of resistance, including expression of 
immune checkpoint molecules (86, 122-129), insufficient infiltration of CD8+ T 
cells (86, 120), oncogenic pathways (43, 44, 130), transcriptomic resistance 
signatures (131), lack of sensitivity to interferon signaling (47, 132-135), defects 
in antigen processing and presentation (40, 47, 136, 137), diversity and 
abundance of bacteria within the gut microbiome (53, 138), and metabolism of 
cancer cells and T cells (139-141). However, additional insights are clearly 
needed for a more comprehensive understanding of resistance. 
        To further refine both host and tumor genomic contributions to resistance to 
checkpoint blockade, we assembled a cohort of longitudinal tissue samples from 
metastatic melanoma patients treated with sequential immune checkpoint 
blockade (CTLA-4 blockade followed by PD-1 blockade at time of progression). 
We previously performed deep immune profiling studies on these samples (via 
immunohistochemistry and gene expression profiling) and identified immune 
biomarkers of response and mechanisms of therapeutic resistance (87). To 
complement these studies, we report here the results of in-depth molecular 
analysis (via whole exome sequencing and T cell receptor sequencing) of these 
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longitudinal samples. These studies have identified putative genomic and 
molecular biomarkers of response and resistance to immune checkpoint 
blockade, demonstrating the complex interplay of host and tumor in treatment 
response. 
 
4.2 Results 
4.2.1 T cell clonality predicts response to PD-1 blockade but not CTLA-4 
blockade 
        We studied a cohort of 56 patients who were first treated with CTLA-4 
blockade, and then subsequently treated with PD-1 blockade at the time of 
progression, with longitudinal tumor samples collected as described in section 
3.2.1 (Patient Cohort, Checkpoint Blockade Treatment, and Longitudinal Tumor 
Biopsies) (Figure 17A, Table 5) by performing whole exome sequencing (WES) 
and TCR sequencing (TCR-seq) on DNA from available tumor samples (Figure 
17A, 18, 19, and Table 6). Responders were defined as patients who had 
complete resolution or partial reduction in the size of tumors by CAT scan-based 
imaging (by at least 30%), or who had prolonged stable disease (for at least 6 
months). Non-responders were defined as patients who had tumor growth of at 
least 20% on CAT scan, or had stable disease lasting less than 6 months. I first 
compared the mutation status of common melanoma driver genes (78, 142) in 
pre-treatment samples, and also assessed interferon-gamma pathway genes, 
given the importance of defects in interferon-gamma signaling in resistance to 
immune checkpoint blockade (45, 47, 143, 144), and found no significant 
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differences between responders and non-responders to therapy with regard to 
somatic point mutations or indels (Fisher’s exact test with a false discovery rate 
threshold of 0.05) (Figure 17B). Next, I compared the frequency of HLA somatic 
mutations (32) in pre-treatment samples and found that HLA somatic mutations 
were found in only one pre-treatment biopsy from a CTLA-4 blockade non-
responder.  
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Figure 17. Patient cohort diagram and genomic landscape of serial tumor 
biopsies. (A) Patients with metastatic melanoma were initially treated with CTLA-4 
blockade (n=56*: * indicates that two of the 56 patients were CTLA-4 blockade naïve. 
Both responded to PD-1 blockade, and only pre-treatment samples were available for 
WES and TCR-seq). Non-responders to CTLA-4 blockade (n=47) were then treated with 
PD-1 blockade. Double non-responders progressed on CTLA-4 blockade first and then 
progressed on PD-1 blockade. Serial tumor biopsies were collected at multiple time 
points (pre-treatment, early on-treatment, and progression on CTLA-4 blockade and PD-
1 blockade, respectively) when feasible. Whole exome sequencing and TCR sequencing 
were performed on these serial tumor biopsies. The numbers in parentheses indicate the 
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number of samples available for responders and non-responders after quality control of 
WES and TCR-seq data. R: responders, NR: non-responders, DNR: double non-
responders. (B) For each sample (columns), genomic profiles (rows) were characterized. 
Column annotations represent biopsy time (Pre-αCTLA4: pre-CTLA-4 blockade samples, 
Pre-αPD1: pre-PD-1 blockade samples, Post-αPD1: post-PD-1 blockade samples) and 
response status (red: responders indicated as R, blue: non-responders indicated as NR, 
*: failed CTLA-4 blockade but responded to PD-1 blockade) for each sample (Sample ID 
denotes patient ID followed by biopsy time: A=pre-αCTLA-4, C=post-CTLA-4/pre-PD-1, 
and E=post-PD-1). Shown at the top of the panel is mutational burden and neoantigen 
burden for each sample. Neoantigens were defined as having an IC50<500nM. Color 
scale shows the range of IC50 from 500nM to 50nM. Synonymous (light) and non-
synonymous (dark) mutations are shown in different shades of blue. Additional genomic 
profiles included selected somatic point mutations, and indels. No indels were found 
among melanoma driver genes. When multiple mutations were found in one gene, the 
following precedence rule was applied: Nonsense mutation > Frame-shift indel > Splice 
site mutation > Missense mutation > In-frame indel.  
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sample patient time aCTLA4_response aPD1_response tumor_purity n_nonsynonymous n_neoantigen n_clones_by_expands n_clones_by_sciclone n_copy_gain n_copy_loss
31A 31 preCTLA4 response NA 0.85 819 997 9 2 88 0
34A 34 preCTLA4 nonresponse response 0.85 3123 5628 17 6 917 1129
50A 50 preCTLA4 nonresponse nonresponse 0.95 3445 6037 17 2 1008 1581
9A 9 preCTLA4 nonresponse response 0.85 84 117 5 3 674 2400
5A 5 preCTLA4 response NA 0.95 404 296 6 3 0 0
7A 7 preCTLA4 nonresponse response 0.85 67 115 4 2 38 0
25A 25 preCTLA4 nonresponse nonresponse 0.95 273 477 12 3 33 1675
32A 32 preCTLA4 nonresponse nonresponse 0.75 77 72 5 2 359 2051
47A 47 preCTLA4 nonresponse response 0.85 2047 2958 9 3 3 0
41A 41 preCTLA4 nonresponse nonresponse 0.95 172 176 8 4 579 2285
20A 20 preCTLA4 nonresponse nonresponse 0.9 2520 3982 14 2 0 161
33A 33 preCTLA4 nonresponse nonresponse 0.9 232 266 5 1 31 0
12A 12 preCTLA4 response NA 0.95 242 311 9 6 453 171
54A 54 preCTLA4 nonresponse nonresponse 0.85 514 686 14 10 283 1012
18A 18 preCTLA4 nonresponse nonresponse 0.95 71 124 7 2 715 110
28A 28 preCTLA4 nonresponse nonresponse 0.6 596 372 12 5 0 993
53A 53 preCTLA4 nonresponse nonresponse 0.9 555 1114 17 8 325 1481
22A 22 preCTLA4 response NA 0.85 589 901 8 3 699 130
23A 23 preCTLA4 nonresponse nonresponse 0.95 69 75 4 2 442 1326
6B 6 onCTLA4 nonresponse response 0.85 63 52 6 2 14 45
22B 22 onCTLA4 response NA 0.95 52 74 6 2 32 938
37B 37 onCTLA4 response NA 0.5 78 155 3 1 62 0
18C 18 postCTLA4_prePD1 nonresponse nonresponse 0.4 64 103 3 1 209 119
24C 24 postCTLA4_prePD1 nonresponse response 0.95 1101 1110 17 5 1 0
33C 33 postCTLA4_prePD1 nonresponse nonresponse 0.9 611 627 13 4 208 1106
50C 50 postCTLA4_prePD1 nonresponse nonresponse 0.8 3388 5961 12 3 0 7
15C 15 postCTLA4_prePD1 NA response 0.9 842 1453 11 5 827 995
9C 9 postCTLA4_prePD1 nonresponse response 0.9 90 122 5 3 458 41
26C 26 postCTLA4_prePD1 nonresponse nonresponse 0.85 1365 2852 15 5 56 4149
29C 29 postCTLA4_prePD1 nonresponse nonresponse 0.95 316 161 10 6 362 0
25C 25 postCTLA4_prePD1 nonresponse nonresponse 0.95 266 551 11 5 146 2716
16C 16 postCTLA4_prePD1 nonresponse nonresponse 0.95 883 1286 15 6 1101 2194
21C 21 postCTLA4_prePD1 nonresponse nonresponse 0.9 647 1039 12 4 464 0
54C 54 postCTLA4_prePD1 nonresponse nonresponse 0.8 484 608 11 3 101 0
3C 3 postCTLA4_prePD1 nonresponse nonresponse 0.8 328 499 11 6 0 217
4D 4 onPD1 nonresponse nonresponse 0.85 128 301 9 5 6 1111
7D 7 onPD1 nonresponse response 0.1 18 25 3 1 0 0
9D 9 onPD1 nonresponse response 0.2 63 103 4 1 0 0
1D 1 onPD1 nonresponse nonresponse 0.85 108 144 10 6 964 4919
16D 16 onPD1 nonresponse nonresponse 0.95 895 1562 14 4 574 2
28D 28 onPD1 nonresponse nonresponse 0.95 610 371 13 4 646 698
47D 47 onPD1 nonresponse response 0.2 299 438 3 2 0 0
3D1 3 onPD1 nonresponse response 0.45 119 144 3 2 4 0
3D2 3 onPD1 nonresponse nonresponse 0.3 137 176 3 1 0 0
53D 53 onPD1 nonresponse nonresponse 0.75 631 1416 13 8 402 1458
26E 26 postPD1 nonresponse nonresponse 0.95 1259 2619 15 5 60 3665
49E 49 postPD1 nonresponse nonresponse 0.9 1439 2473 16 3 158 2979
20E 20 postPD1 nonresponse nonresponse 0.85 2484 3950 10 5 NA NA
42E 42 postPD1 nonresponse nonresponse 0.95 212 287 10 6 688 2989
45E 45 postPD1 nonresponse nonresponse 0.85 499 184 12 1 NA NA
2E 2 postPD1 nonresponse nonresponse 0.9 211 172 11 3 1570 2815
 
Table 5. Sample information, tumor purity, mutational load, neoantigen load, 
number of clones per tumor, and burden of copy number alterations 
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Figure 18. Workflow diagram of multidimensional profiling analysis. Peripheral 
blood and serial tumor biopsies were collected from patients (n=56). Using DNA and 
RNA extracted from formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, we 
performed whole exome sequencing and TCR sequencing. NanoString gene expression 
profiling data were obtained from immune profiling. Genomic profiles (red) were 
characterized from whole exome sequencing data. Immune profiles (blue) were 
characterized from TCR sequencing data and NanoString gene expression data. 
Characterized genomic profiles included somatic point mutations, indels, HLA somatic 
mutations, copy number alterations, neoantigens, and intratumor heterogeneity 
measures (number of clones per tumor). TCR clonality was derived from enumeration of 
identified TCR clonotypes. Immune scores were calculated from gene expression of 
selected immune-related genes (cytolytic markers, HLA molecules, IFN-γ pathway, 
chemokines, and adhesion molecules). Bolded text shows the variables analyzed. Italics 
show the software used to generate the associated variables 
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Figure 19. Distribution of sequencing coverage and tumor purities across 
samples. (A) The difference of mean sequencing coverage across groups stratified by 
five biopsy time points and response status (NR: non-responders, R: responders). (B) 
The difference of tumor purities across groups stratified by five biopsy time points and 
response status. Tumor purity was assessed by two pathologists. 
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Timepoint Pre+CTLA+4 Pre+CTLA+4 On+CTLA+4 On+CTLA+4
Response response nonresponse response nonresponse
Mutational7load 513$(248) 923$(1209) 65$(18) 63$(0)
Neoantigen7load 626$(374) 1479$(2106) 114$(57) 52$(0)
Burden7of7copy7number7loss 75$(88) 1080$(856) 469$(663) 45$(0)
Immune7scores 7$(0.6) 8$(0.54) 9.1$(0.98) 7.1$(0.85)
TCR7clonality 0.013$(0.008) 0.02$(0.02) 0.158$(0.118) 0.044$(0.03)
Timepoint Post+CTLA+4/Pre+PD+1 Post+CTLA+4/Pre+PD+1 On+PD+1 On+PD+1 Post+PD+1
Response response nonresponse response nonresponse nonresponse
Mutational7load 677$(525) 835$(969) 124$(123) 418$(337) 1017$(889)
Neoantigen7load 895$(691) 1368$(1795) 177$(180) 661$(647) 1614$(1618)
Burden7of7copy7number7loss 345$(563) 1050$(1477) 0$(0) 1364$(1836) 3112$(377)
Immune7scores 8$(1.5) 8.4$(1.3) 10.5$(0.48) 6.7$(0.94) 7.8$(1.2)
TCR7clonality 0.11$(0.09) 0.041$(0.046) 0.145$(0.08) 0.015$(0.01) 0.074$(0.055)
*$Mean$value$(standard$deviation)  
Table 6. Summary measure of the data across clinical subgroups 
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        In our cohort, we did not observe any statistically significant differences in 
mutational load or predicted neoantigen load in pre-treatment samples from 
responders versus non-responders to therapy by either CTLA-4 or PD-1 
blockade (Figure 20A-20B) (mutational load: P = 0.597 in pre-CTLA-4 blockade 
samples, P = 0.937 in pre-PD-1 blockade samples; neoantigen load: P = 0.736 in 
pre-CTLA-4 blockade samples, P = 0.937 in pre-PD-1 blockade samples), which 
is in contrast to published literature (25, 41, 75, 119) and may be due to limited 
sample size. Further, no significant differences were observed in intratumor 
heterogeneity (ITH), estimated as the number of clones per tumor, between 
responders and non-responders to immune checkpoint blockade (Figure 21). 
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Figure 20. Mutational load, neoantigen load, and clinical response. Boxplots 
summarize mutational load (A) and neoantigen load (B) by response status (blue: non-
responders, red: responders) in pre-CTLA-4 blockade samples and pre-PD-1 blockade 
samples; median values (lines) and interquartile range (whiskers) are indicated. P values 
were calculated using a two-sided Mann-Whitney U test (P = 0.597 in pre-CTLA-4 
blockade samples, P = 0.937 in pre-PD-1 blockade samples for mutational load; P = 
0.736 in pre-CTLA-4 blockade samples, P = 0.937 in pre-PD-1 blockade samples for 
neoantigen load). 
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Figure 21. Intratumor heterogeneity and clinical response. Intratumor heterogeneity 
was estimated as the number of clones per tumor for each sample. The number of 
clones per tumor was estimated by EXPANDS and SciClone independently. There was 
moderate correlation between the estimated number of clones per tumor from two 
algorithms (correlation coefficient = 0.59; Spearman rank correlation, P = 0.00037). 
Boxplots summarize the number of clones per tumor estimated from each software by 
response status (blue: non-responders, red: responders) in pre-CTLA-4 blockade 
samples and pre-PD-1 blockade samples; median values (lines) and interquartile range 
(whiskers) are indicated. P values were calculated using a two-sided Mann-Whitney U 
test (P > 0.05 for all). 
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        We next performed sequencing of the CDR3 variable region of the β-chain 
of the T cell receptor (TCR-seq) to understand the role of the T cell repertoire in 
response and resistance to checkpoint blockade (Table 7). Although no 
significant differences were observed in TCR clonality when comparing 
responders to non-responders in the context of CTLA-4 blockade at the pre-
treatment (P = 0.96) and on-treatment time points (P = 0.2) (Figure 22), an 
increase in clonality was noted in a subset of patients treated with CTLA-4 
blockade (Figure 23). Among 8 patients with matched longitudinal tumor samples 
(pre-CTLA-4 and pre-PD-1, n=8) available, all three PD-1 blockade responders 
showed an increase in TCR clonality on CTLA-4 blockade, whereas this was the 
case in only 1 out of 5 non-responders to PD-1 blockade (Figure 23). The one 
patient (Patient 50) classified as a non-responder in the context of the trial criteria 
who demonstrated an increase in clonality appeared to have some clinical benefit 
from treatment with PD-1 blockade, as he continued on PD-1 blockade therapy 
for a total of 24 doses and had no evidence of disease at last follow up. Higher 
TCR clonality was observed in responders to PD-1 blockade at both pre- (P = 
0.037) and on-treatment (P = 0.032) time points (Figure 22).  
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sample patient time aCTLA4_response aPD1_response Clonality
10A 10 preCTLA4 response NA 0.05527087
10B 10 onCTLA4 response NA 0.04997955
12A 12 preCTLA4 response NA 0.01794051
15C 15 postCTLA4_prePD1 NA response 0.00582951
16C 16 postCTLA4_prePD1 nonresponse nonresponse 0.01731895
16D 16 onPD1 nonresponse nonresponse 0.01817108
18A 18 preCTLA4 nonresponse nonresponse 0.0544221
18B 18 onCTLA4 nonresponse nonresponse 0.01083352
18C 18 postCTLA4_prePD1 nonresponse nonresponse 0.05261548
19D 19 onPD1 nonresponse nonresponse 0.00829378
19E 19 postPD1 nonresponse nonresponse 0.0546851
1B 1 onCTLA4 nonresponse nonresponse 0.05518331
1D 1 onPD1 nonresponse nonresponse 0.02867525
22B 22 onCTLA4 response nonresponse 0.07514578
23A 23 preCTLA4 nonresponse nonresponse 0.02615795
23B 23 onCTLA4 nonresponse nonresponse 0.08747733
24A 24 preCTLA4 nonresponse response 0.08637499
24C 24 postCTLA4_prePD1 nonresponse response 0.14294231
24D 24 onPD1 nonresponse response 0.23178676
25A 25 preCTLA4 nonresponse nonresponse 0.02639377
25C 25 postCTLA4_prePD1 nonresponse nonresponse 0.01237117
25E 25 postPD1 nonresponse nonresponse 0.00649915
26E 26 postPD1 nonresponse nonresponse 0.1357679
27B 27 onCTLA4 response nonresponse 0.1382599
2A 2 preCTLA4 nonresponse nonresponse 0.00428925
2E 2 postPD1 nonresponse nonresponse 0.03395957
31A 31 preCTLA4 response nonresponse 0.01887839
33C 33 postCTLA4_prePD1 nonresponse nonresponse 0.07783938
37A 37 preCTLA4 response NA 0.03382181
37B 37 onCTLA4 response NA 0.24256822
3A 3 preCTLA4 nonresponse nonresponse 0.01494006
3C 3 postCTLA4_prePD1 nonresponse nonresponse 0.01626247
3D1 3 onPD1 nonresponse response 0.02786906
40C 40 postCTLA4_prePD1 nonresponse nonresponse 0.00144045
42C 42 postCTLA4_prePD1 nonresponse nonresponse 0.04860959
42E 42 postPD1 nonresponse nonresponse 0.02891788
45E 45 postPD1 nonresponse nonresponse 0.05604353
47A 47 preCTLA4 nonresponse response 0.01718291
47D 47 onPD1 nonresponse response 0.17340681
49C 49 postCTLA4_prePD1 nonresponse nonresponse 0.02107852
49E 49 postPD1 nonresponse nonresponse 0.03817971
4A 4 preCTLA4 nonresponse nonresponse 0.00437446
4C 4 postCTLA4_prePD1 nonresponse nonresponse 0.0021321
4D 4 onPD1 nonresponse nonresponse 0.00511381
50A 50 preCTLA4 nonresponse nonresponse 0.02263149
50C 50 postCTLA4_prePD1 nonresponse nonresponse 0.16309696
50E 50 postPD1 nonresponse nonresponse 0.17025982
52C 52 postCTLA4_prePD1 nonresponse response 0.17419149
54C 54 postCTLA4_prePD1 nonresponse nonresponse 0.04147743
56D 56 onPD1 nonresponse response 0.21286792
5A 5 preCTLA4 response nonresponse 0.00323339
6B 6 onCTLA4 nonresponse response 0.02449196
6C2 6 postCTLA4_prePD1 nonresponse response 0.07375047
7A 7 preCTLA4 nonresponse nonresponse 0.02885111
7D 7 onPD1 nonresponse response 0.14695446
8A 8 preCTLA4 nonresponse response 0.02901636
8C 8 postCTLA4_prePD1 nonresponse response 0.25088206
9A 9 preCTLA4 nonresponse response 0.02939994
9C 9 postCTLA4_prePD1 nonresponse response 0.23396692  
Table 7. TCR clonality 
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Figure 22. TCR clonality and clinical response. Boxplots summarize TCR clonality by 
response status (blue: non-responders, red: responders) in pre-CTLA-4 blockade 
samples, pre-PD-1 blockade samples, on-CTLA-4 blockade samples, and on-PD-1 
blockade samples, respectively; median values (lines) and interquartile range (whiskers) 
are indicated. P values were calculated using a two-sided Mann-Whitney U test (P > 
0.05 for TCR clonality in pre-CTLA-4 blockade and on-CTLA-4 blockade samples, P = 
0.037 for TCR clonality in pre-PD-1 blockade samples and P = 0.032 for TCR clonality in 
on-PD-1 blockade samples.). 
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Figure 23. The effects of previous CTLA-4 blockade exposure on the baseline TCR 
clonality of pre-PD-1 blockade samples. Data show the patient-matched TCR clonality 
at two time points (pre-CTLA-4 and pre-PD-1) (red line: PD-1 blockade responders, blue 
line: PD-1 blockade non-responders, *: PD-1 blockade non-responder, Patient 50, who 
continued on with pembrolizumab off protocol for a total of 24 doses and had no 
evidence of disease at last follow up). 
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        Next, I sought to investigate the association between TCR clonality and 
immune activation in the tumor microenvironment. To do so, I first calculated the 
immune score from gene expression profiling data in our cohort. The immune 
score was defined as the geometric mean of gene expression in selected genes 
including cytolytic markers, HLA molecules, IFN-γ pathway, selected 
chemokines, and adhesion molecules related to tumor rejection in the context of 
the immunologic constant of rejection (145, 146) (Table 8). Although no 
association was observed between TCR clonality and immune scores in pre-
CTLA-4 blockade samples, a significant positive correlation was observed 
between TCR clonality and immune scores in pre-PD-1 blockade samples (P = 
0.0018, Figure 24).  
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sample immune*score
5A 8.17
7A 8.55
8A 7.76
9A 7.83
10A 7.53
18A 7.82
19A 8.02
22A 6.86
23A 7.54
25A 8.8
31A 8.2
37A 8.23
42A 9.32
43A 7.21
47A 7.54
50A 7.13
6B 7.78
18B 6.57
22B 8.47
27B 10.45
37B 9.86
2C 10.12
3C 8.6
4C 7.59
6C1 7.22
6C2 6.08
8C 10.17
9C 9.84
15C 7.86
16C 7.62
18C 9.72
24C 9.31
25C 6.05
49C 8.3
50C 8.67
52C 9.88
54C 9.14
1D 6.45
3D1 10.04
4D 5.48
7D 10.48
9D 10.04
16D 8.08
19D 6.55
24D 11.22
40D 7.06
47D 10.5
2E 8.11
19E 5.84
26E 7.04
43E 6.03
45E 8.74
49E 9.06
50E 8.46  
Table 8. Immune scores (NanoString) in our cohort 
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Figure 24. The correlation between TCR clonality and immune scores. Data show 
the correlation between TCR clonality and immune scores for the pre-CTLA-4 blockade 
biopsies and the pre-PD-1 blockade biopsies. Spearman rank correlation was used for 
correlation coefficient. 
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4.2.2 High copy number loss burden is associated with poor response to 
immune checkpoint blockade 
        Given the lack of clear differences in point mutation and indel status in 
driver genes between responders and non-responders to CTLA-4 and PD-1 
blockade, I then investigated whether copy number alterations (CNAs) may play 
a role in response and resistance to CTLA-4 and PD-1 blockade. With regards to 
specific genes, I did not find any significant association between copy number 
gain or loss status and response to therapy in pre-treatment biopsies for either 
therapy (Fisher’s exact test with a false discovery rate threshold of 0.05). Given a 
recent report demonstrating the impact of loss of HLA Class I and β2-
microglobulin in resistance to cytolytic activity (40), I next examined the 
relevance of copy number loss in these genes within our cohort. In this study, 
although we observed no significant loss of HLA class I genes, loss of β2-
microglobulin was detected in 4 non-responders to CTLA-4 blockade (with focal 
copy number loss in 2 patients and arm-level copy number loss in 2 patients). 
Focal copy number loss of β2-microglobulin was also observed in 1 pre-
treatment sample from a CTLA-4 blockade naïve PD-1 blockade responder. To 
assess CNAs at the whole genome sample level, I defined burden of CNAs as 
the total number of genes with copy number gain or loss per sample. On testing 
the association between burden of CNAs and response to therapy in pre-
treatment biopsies of patients on CTLA-4 or PD-1 blockade, we observed no 
significant differences in burden of copy number gain or loss (P > 0.05 for all 
comparisons) in the context of individual agent response (Figure 25). However, a 
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trend toward higher burden of copy number loss was observed in pre-CTLA-4 
blockade biopsies from CTLA-4 blockade responders compared to CTLA-4 
blockade non-responders, though statistical significance was not attained (P = 
0.077).  
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Figure 25. Burden of copy number alterations in responders versus non-
responders. Boxplots summarize burden of copy number gain or loss in four groups of 
interest: pre-CTLA-4 blockade responders, pre-CTLA-4 blockade non-responders, pre-
PD-1 blockade responders, and pre-PD-1 blockade non-responders; median values 
(lines) and interquartile range (whiskers) are indicated. P values were calculated using a 
two-sided Mann-Whitney U test. (P = 0.077 for pre-CTLA-4 blockade responders vs. 
non-responders, P = 0.607 for pre-PD-1 blockade responders vs. non-responders, and P 
> 0.05 for all others) NR: non-responders, R: responders. 
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        I next investigated the burden of copy number alterations in pre-CTLA-4 
blockade biopsies from patients who progressed on CTLA-4 blockade first and 
then progressed on PD-1 blockade, termed double non-responders (DNRs) 
because we hypothesized that the association between burden of copy number 
alterations and resistance might be stronger in patients with potentially more 
resistant phenotype (failure on both treatments) than in patients who failed a 
single agent. We observed no significant differences in burden of copy number 
gain but significantly higher burden of copy number loss in pre-CTLA-4 blockade 
biopsies from DNRs compared to pre-CTLA-4 blockade biopsies from CTLA-4 
blockade responders (P = 0.042) (Figure 26 and 27). We noted a strikingly higher 
burden of copy number loss in post-PD-1 blockade biopsies compared to pre-
CTLA-4 blockade biopsies from CTLA-4 blockade responders (P = 0.029) (Fig 
2A, fig. S7). The burden of copy number loss was not correlated with mutational 
load at any of the time points studied (Figure 28), suggesting that the association 
is not readily attributable to decreased mutational burden. 
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Figure 26. Burden of copy number alterations in responders versus double non-
responders. Boxplots summarize burden of copy number gain or loss in five groups of 
interest: responders to CTLA-4 blockade at pre-treatment, pre-CTLA-4 blockade double 
non-responders, responders to PD-1 blockade at pre-treatment, pre-PD-1 blockade 
double non-responders, and post-PD-1 blockade double non-responders; median values 
(lines) and interquartile range (whiskers) are indicated. P values were calculated using a 
two-sided Mann-Whitney U test. (P = 0.042 for pre-CTLA-4 blockade responders vs. 
double non-responders, P = 0.029 for pre-CTLA-4 blockade responders vs. post-PD-1 
blockade double non-responders, and P > 0.05 for all others) DNR: double non-
responders, NR: non-responders, R: responders. In bold are highlighted the Pre-CTLA-4 
blockade and Post-PD-1 blockade double non-responder (DNR) groups.   
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Figure 27. Copy number profiles of responders and double non-responders. Copy 
ratios (tumor/normal) were plotted in genomic coordinates for responders (pre-CTLA-4 
blockade, pre-PD-1 blockade) and double non-responders (post-PD-1 blockade). Red 
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lines indicate copy number segmented values. The dotted lines indicate the copy 
number. 
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Figure 28. Correlation between burden of copy number loss and mutational load. 
Data show the correlation between burden of copy number loss and mutational load. 
Spearman rank correlation was used for correlation coefficient (correlation coefficient = -
0.18; Spearman rank correlation, P = 0.53 for pre-CTLA-4 blockade samples, correlation 
coefficient = 0.07, P = 0.82 for pre-PD-1 blockade samples, correlation coefficient = 0.4, 
P = 0.75 for post-PD-1 blockade double non-responder samples.). 
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        To gain insight into mechanisms through which CNAs could influence 
response to therapy, I next investigated if there were any recurrent regions of 
copy number loss in double non-responders with high burden of copy number 
loss (> 2,000 genes with copy number loss). Recurrent copy number loss was 
observed at the arm level in chromosome 6q and 10q, and recurrent focal copy 
number loss was observed in 8p23.3, 11p15.5, 11q23, 11q24, and 11q25 (Figure 
29, Table 9). In these regions with recurrent copy number loss, tumor suppressor 
genes were located in chromosomes 6q (FOXO3, PRDM1, PTPRK, TNFAIP3, 
and ESR1), 10q (NCOA4, BMPR1A, PTEN, FAS, SUFU, and TCF7L2), and 
11q23.3 (CBL, ARHGEF12). These data suggest that high burden of copy 
number loss in double non-responders is associated with recurrent copy number 
loss in tumor suppressor genes located in chromosomes 6q, 10q, and 11q23.3. 
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Figure 29. Recurrent copy number loss in double non-responders. Segment Gain 
or Loss (SGOL) scores were calculated for each copy number segments as sum of log2 
copy ratios (tumor/normal) of each copy number segment across all double non-
responder samples with burden of copy number loss higher than 2,000 (n=9). Higher 
positive SGOL scores indicate higher copy number gain of copy number segments and 
lower negative SGOL scores indicate higher copy number loss of copy number 
segments. Tumor suppressor genes with recurrent copy number loss are indicated in 
chromosome 6q, 10q, and 11q23.3. 
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Recurrent(Samples Status Chromosome MCR.start MCR.end Cytobands
32A,41A,25C,49E,2E loss chr6 64694354 100061533 q12,q13,q14.1,q14.2,q14.3,q15,q16.1,q16.2
32A,41A,26C,25C,49E,2E loss chr6 100061533 126210395 q16.2,q16.3,q21,q22.1,q22.2,q22.31,q22.32
32A,41A,26C,25C,2E loss chr6 126210395 129722389 q22.32,q22.33
32A,41A,26C,25C,49E,2E loss chr6 129722389 134304023 q22.33,q23.1,q23.2
32A,41A,26C,49E,2E loss chr6 134304023 136359446 q23.2,q23.3
26E,32A,41A,26C,49E loss chr6 137026266 137519127 q23.3
26E,32A,41A,26C,49E,2E loss chr6 137519127 170190200 q23.3,q24.1,q24.2,q24.3,q25.1,q25.2,q25.3,q26,q27
32A,41A,26C,49E,2E loss chr6 170190200 170595317 q27
26E,41A,26C,49E,2E loss chr8 182934 2148771 p23.3
26E,32A,41A,26C,2E gain chr8 144789269 146115367 q24.3
41A,25C,16C,49E,42E,2E loss chr10 42965636 45939136 q11.21
41A,25C,49E,42E,2E loss chr10 45939136 45958881 q11.21
41A,25C,49E,42E,2E loss chr10 46965017 46965018 q11.22
41A,25C,16C,49E,42E,2E loss chr10 46965727 47000146 q11.22
41A,25C,49E,42E,2E loss chr10 47000146 47087609 q11.22
41A,25C,49E,42E,2E loss chr10 48429578 116251686 q11.22,q11.23,q21.1,q21.2,q21.3,q22.1,q22.2,q22.3,q23.1,q23.2,q23.31,q23.32,q23.33,q24.1,q24.2,q24.31,q24.32,q24.33,q25.1,q25.2,q25.3
41A,25C,49E,42E,2E loss chr10 118355695 127436411 q25.3,q26.11,q26.12,q26.13
41A,25C,49E,42E,2E loss chr10 127461154 127530325 q26.13,q26.2
41A,16C,49E,42E,2E loss chr10 127708428 127734716 q26.2
41A,25C,16C,49E,42E,2E loss chr10 127734716 135216340 q26.2,q26.3
41A,25C,16C,49E,42E loss chr10 135216340 135269955 q26.3
26E,26C,25C,49E,42E loss chr11 1021268 1212967 p15.5
26E,26C,25C,49E,42E loss chr11 1213174 1213177 p15.5
26E,26C,25C,49E,42E loss chr11 1213204 1213245 p15.5
26E,41A,26C,25C,49E,42E loss chr11 1213245 1213533 p15.5
26E,26C,25C,49E,42E loss chr11 1215580 1253942 p15.5
26E,26C,25C,49E,42E loss chr11 1255773 1309956 p15.5
26C,25C,16C,42E,2E loss chr11 118765267 134202036 q23.3,q24.1,q24.2,q24.3,q25
*MCR:@Minimum@Common@Regions@(by@cghMCR)  
Table 9. Recurrent copy number alterations in double non-responders with burden 
of copy number loss > 2000 
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4.2.3 An independent patient cohort shows copy number loss as a putative 
resistance mechanism 
        To investigate the impact of higher burden of copy number loss on 
resistance in another cohort of patients on immune checkpoint blockade, we 
obtained WES SAM files from 110 melanoma patients and RNA-seq data from a 
subset of 42 melanoma patients (25) and reanalyzed the data utilizing the same 
informatics pipeline and calling criteria. I then tested the association between the 
burden of CNAs (Table 10) and response to therapy in pre-treatment biopsies on 
CTLA-4 blockade using the same response criteria (clinical benefit, long-term 
survival with no clinical benefit, and minimal or no clinical benefit) as previously 
described (25). Although the burden of copy number gain was not significantly 
associated with clinical benefit from CTLA-4 blockade, a lower burden of copy 
number loss was significantly associated with clinical benefit (P = 0.016) (Figure 
30). As observed in our cohort, the burden of copy number loss once again did 
not correlate with mutational load (Figure 31). When examining the regions 
associated with recurrent copy number loss in the no clinical benefit subgroup, 
recurrent copy number loss was observed at arm level in chromosome 9p and 
10q, and recurrent focal copy number loss was observed in 4q35.2, 6q25, 6q27, 
and 11p15.5 (Figure 32). Among these regions, tumor suppressor genes were 
observed in 6q25.1 (ESR1) and 10q (NCOA4, BMPR1A, PTEN, FAS, and 
SUFU), as seen within our cohort. Of note, no recurrent copy number loss was 
observed in any tumor suppressor gene in the clinical benefit subgroup and long-
term survival subgroup.  
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patient group n_copy_gain n_copy_loss
Pat02 response 27 1471
Pat03 nonresponse 0 865
Pat04 response 164 2971
Pat06 nonresponse NA NA
Pat07 response 820 753
Pat08 nonresponse 162 3976
Pat100 nonresponse 4 1099
Pat101 nonresponse 771 4100
Pat103 response 0 0
Pat104 nonresponse 1070 12
Pat105 response 0 0
Pat106 nonresponse NA NA
Pat109 nonresponse 0 328
Pat11 long8survival 27 0
Pat110 nonresponse 11 1152
Pat113 response 845 4053
Pat115 nonresponse 679 8146
Pat117 response 0 98
Pat118 nonresponse 430 65
Pat119 long8survival 157 2811
Pat121 nonresponse NA NA
Pat123 response 0 0
Pat124 nonresponse 1012 2573
Pat126 response 435 533
Pat127 nonresponse 937 6204
Pat128 nonresponse 1554 118
Pat129 nonresponse 683 1093
Pat13 long8survival 0 264
Pat130 nonresponse 344 6043
Pat131 nonresponse 29 0
Pat132 response NA NA
Pat133 nonresponse 329 695
Pat135 nonresponse 711 2929
Pat138 response 145 217
Pat139 nonresponse 755 4170
Pat14 nonresponse 356 132
Pat140 nonresponse 1076 453
Pat143 nonresponse 869 5385
Pat147 nonresponse 0 18
Pat148 nonresponse 13 1576
Pat15 nonresponse 1466 4970
Pat151 nonresponse 198 1722
Pat157 nonresponse 642 2619
Pat159 long8survival 123 2002
Pat16 long8survival 318 2139
Pat160 nonresponse 2780 2244
Pat162 nonresponse 767 2096
Pat163 long8survival 149 2910
Pat165 nonresponse NA NA
Pat166 nonresponse NA NA
Pat167 nonresponse 884 2319
Pat168 nonresponse 1308 3186
Pat17 nonresponse 155 1948
Pat170 nonresponse 0 1893  
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Pat171 nonresponse NA NA
Pat174 response 0 65
Pat175 nonresponse NA NA
Pat18 long5survival 304 246
Pat19 nonresponse 141 183
Pat21 response 125 0
Pat24 response 367 660
Pat25 nonresponse 0 0
Pat27 long5survival 456 0
Pat28 long5survival 0 0
Pat29 response 84 0
Pat32 nonresponse 451 2
Pat33 nonresponse 122 329
Pat36 nonresponse 34 0
Pat37 nonresponse 1281 3368
Pat38 response 253 72
Pat39 response 12 0
Pat40 nonresponse 177 1779
Pat41 nonresponse 0 1883
Pat43 nonresponse 799 1059
Pat44 nonresponse 0 1310
Pat45 nonresponse 513 5015
Pat46 nonresponse 296 1497
Pat47 response 177 1727
Pat49 response 285 0
Pat50 nonresponse 246 4819
Pat54 nonresponse 7 1861
Pat55 nonresponse 141 1174
Pat56 nonresponse 684 5341
Pat57 nonresponse 669 1403
Pat58 nonresponse 198 4857
Pat59 nonresponse 106 0
Pat60 nonresponse 443 131
Pat62 nonresponse 0 1658
Pat63 response 317 1213
Pat64 nonresponse 1207 1429
Pat66 response 1073 100
Pat67 nonresponse 404 1795
Pat70 nonresponse 452 1502
Pat71 nonresponse 0 10
Pat73 response NA NA
Pat74 nonresponse 267 1468
Pat76 nonresponse 0 84
Pat77 response 0 27
Pat78 nonresponse NA NA
Pat79 response 472 2815
Pat80 response 1211 3403
Pat81 nonresponse NA NA
Pat82 nonresponse 297 2101
Pat83 long5survival 448 0
Pat85 nonresponse 143 0
Pat86 nonresponse 682 3385
Pat88 response 621 2017
Pat90 response 978 6764
Pat92 nonresponse NA NA
Pat98 nonresponse 471 1635  
Table 10. Burden of copy number alterations in the Van Allen cohort 
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Figure 30. Burden of copy number alterations in each clinical response group 
from an independent cohort. Boxplots summarize burden of copy number gain or loss 
in three patient subgroups from the Van Allen cohort: clinical benefit, long-term survival 
with no clinical benefit, and minimal or no clinical benefit; median values (lines) and 
interquartile range (whiskers) are indicated. P values were calculated using a two-sided 
Mann-Whitney U test (P = 0.016 for burden of copy number loss in clinical benefit vs. 
minimal or no clinical benefit, and P > 0.05 for all others). 
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Figure 31. Correlation between burden of copy number loss and mutational load in 
the Van Allen cohort. Data show the correlation between burden of copy number loss 
and mutational load in Van Allen cohort. Spearman rank correlation was used for 
correlation coefficient (correlation coefficient = -0.028, P = 0.79). 
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Figure 32. Segment Gain or Loss (SGOL) scores in three patient subgroups from 
the Van Allen cohort. Plots show the recurrent copy number alterations in genomic 
coordinates. SGOL scores were calculated as sum of log2 copy ratios of copy number 
segment in each group (sample size of each group is indicated in parentheses). In 
minimal or no clinical benefit group, samples with burden of copy number loss lower than 
100 (Pat25, Pat32, Pat36, Pat59, Pat71, Pat76, Pat85, Pat104, Pat118, Pat131, and 
Pat147) were excluded from analysis. Higher positive SGOL scores indicate higher copy 
number gain in copy number segments, and lower negative SGOL scores indicate 
higher copy number loss in copy number segments. Copy number segments with both 
copy number gain and copy number loss present were excluded. Tumor suppressor 
genes with recurrent copy number loss are indicated. 
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        Next, I investigated whether the recurrent region of copy number loss 
identified in our cohort (Table 9) is also associated with CTLA-4 blockade 
resistance in this independent cohort (Van Allen cohort).  To do so, I calculated 
the burden of copy number loss in this independent cohort as the total number of 
genes with copy number loss in the recurrent regions of copy number loss 
identified in our cohort. We observed a significantly higher burden of copy 
number loss in the minimal or no clinical benefit groups compared to the clinical 
benefit group (P = 0.0034) (Figure 33). This result suggests that the recurrent 
regions of copy number loss in our cohort are also associated with CTLA-4 
blockade resistance in this independent cohort.  
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Figure 33. Burden of recurrent CNAs in patients in Van Allen cohort. Boxplots 
summarize burden of copy number gain or loss in recurrent regions of copy number loss 
identified from our cohort in each response group from the Van Allen cohort; median 
values (lines) and interquartile range (whiskers) are indicated. P values were calculated 
using a two-sided Mann-Whitney U test. (P = 0.0034 for clinical benefit group vs. minimal 
or no clinical benefit group, and P > 0.05 for all others)  
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       I next sought to determine the relative contribution of copy number loss 
burden from chromosome 10 in CTLA-4 blockade resistance. I was specifically 
interested in copy number loss from chromosome 10 because a recent study 
(147) showed functional evidence that recurrent loss of the entire chromosome 
10 can result in collective repression of multiple tumor suppressor genes. This is 
also consistent with the observation that chromosome 10 harbored the largest 
number of tumor suppressor genes with recurrent copy number loss in both our 
cohort (Figure 29) and the independent cohort (Figure 32). The logistic 
regression model showed that the odds of resistance to CTLA-4 blockade were 
exp(1.504) = 4.5 (95% CI: 1.56 – 13) times greater in patients with high burden of 
copy number loss in chromosome 10 than in patients with low burden of copy 
number loss in chromosome 10 (Table 11) and the odds of resistance were 
exp(1.069) = 2.91 (95% CI: 1.07 – 7.89) times greater in patients with high 
burden of copy number loss outside chromosome 10 than in patients with low 
burden of copy number loss outside chromosome 10 (Table 12). Therefore, the 
relative contribution of copy number loss burden from chromosome 10 in CTLA-4 
blockade resistance was higher than copy number loss burden outside 
chromosome 10. I further investigated the extent to which PTEN loss in 
chromosome 10 is associated with CTLA-4 blockade resistance (44). In our data, 
the odds of resistance were 5.58 times greater in patients with PTEN loss than in 
patients with no PTEN loss (95% CI: 1.19 - 26.20) (Table 13), suggesting that 
PTEN loss is likely to be one of the driver resistance mechanisms exploited by 
tumors with high burden of copy number loss on chromosome 10.  
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Estimate SE Z*value P*value
Intercept 1.922 1.136 1.691 0.091
Log2(Mutational:load) (0.206 0.135 (1.52 0.128
Burden:of:copy:number:loss:(high:or:low):::chr10:only 1.504 0.541 2.779 0.005  
Table 11. Relative contribution of copy number loss burden by chromosome 10 in 
CTLA-4 blockade resistance 
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Estimate SE Z*value P*value
Intercept 2.448 1.134 2.159 0.031
Log2(Mutational:load) *0.254 0.137 *1.85 0.065
Burden:of:copy:number:loss:(high:or:low):::outside:chr10 1.069 0.509 2.1 0.036  
Table 12. Relative contribution of copy number loss burden outside chromosome 
10 in CTLA-4 blockade resistance 
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Estimate SE Z*value P*value
Intercept 2.227 1.124 1.982 0.048
Log2(Mutational:load) )0.207 0.135 )1.53 0.126
PTEN:loss:(loss:or:no:loss) 1.719 0.789 2.178 0.029  
Table 13. Relative contribution of PTEN loss in CTLA-4 blockade resistance 
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4.2.4 Integrated analysis reveals putative mechanisms through which CNAs 
may influence response to therapy 
        In addition to studying the influence of copy number loss on molecular 
features such as tumor suppressor genes, I sought to study the relationship of 
these alterations with the immune tumor microenvironment. To do so, I examined 
the correlation between burden of copy number loss and immune scores. 
Although we observed no correlation between the burden of copy number loss 
and immune scores in pre-CTLA-4 blockade biopsies in our cohort (correlation 
coefficient = -0.13; Spearman rank correlation, P = 0.79), a moderate negative 
correlation between the burden of copy number loss and immune scores 
calculated by ESTIMATE (88) was identified in the Van Allen cohort (correlation 
coefficient = -0.41; Spearman rank correlation, P = 0.011) (25) (Figure 34A). In 
pre-PD-1 blockade biopsies in our cohort, we also observed a negative 
correlation between the burden of copy number loss and immune scores 
(correlation coefficient = -0.63; Spearman rank correlation, P = 0.091) (Figure 
34B), although this could not be investigated in post-PD-1 blockade biopsies due 
to sample size. Our immune scores and those calculated by ESTIMATE (Table 
14) showed a strong positive correlation (correlation coefficient = 0.91; Spearman 
rank correlation, P < 2.2e-16) in the independent cohort (Figure 34C), suggesting 
concordance between immune scores. 
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Figure 34. Correlation between burden of copy number loss and immune scores. 
Data show (A) the correlation between burden of copy number loss and immune scores 
for the pre-CTLA-4 blockade biopsies in our cohort, and the correlation between burden 
of copy number loss and immune scores calculated by ESTIMATE in patients with 
matched copy number data and RNA-seq data available (n=38) from Van Allen cohort, 
(B) the correlation between burden of copy number loss and immune scores for the pre-
PD-1 blockade biopsies in our cohort, and (C) the correlation between immune scores 
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and immune scores calculated by ESTIMATE in Van Allen cohort. Spearman rank 
correlation was used for correlation coefficient. 
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patient immune_score_ESTIMATE
Pat02 2714.41
Pat03 730.23
Pat04 822.98
Pat06 2731.64
Pat08 1338.68
Pat118 1801.37
Pat119 353.57
Pat123 343.53
Pat126 768.27
Pat14 1238.3
Pat15 3919.35
Pat16 735.31
Pat19 2186.07
Pat20 307.95
Pat25 247.77
Pat27 1394.39
Pat28 1630
Pat29 1759.46
Pat33 368.31
Pat36 3233.77
Pat37 416.22
Pat38 2371.01
Pat39 2177.73
Pat40 752.89
Pat41 263
Pat43 2526.03
Pat44 31105.11
Pat45 3957.69
Pat46 1339.92
Pat47 424.87
Pat49 2730.05
Pat50 252.84
Pat79 197.48
Pat80 1323.28
Pat81 356.89
Pat83 1481.38
Pat85 3198.89
Pat86 601.73
Pat88 2018.3
Pat90 635.76
Pat91 1370.99
Pat98 1035.48  
Table 14. Immune scores (RNA-seq) in the Van Allen cohort 
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I further sought to determine which pathways or gene ontologies (GO) 
were enriched in up/down-regulated genes at the mRNA expression level in the 
high burden of copy number loss (n=10; mean: 4149, range: 2815 to 6764) 
versus low burden of copy number loss (n=10; mean: 0) groups within the Van 
Allen cohort. Gene set enrichment analysis (GSEA) (89) showed that immune-
related pathways were enriched among down-regulated genes, whereas cell 
cycle-related pathways were enriched among up-regulated genes (Figure 35 and 
36A). Similar results were found with GO terms (Figure 36B). Collectively, these 
data suggest that high burden of copy number loss may be associated with 
down-regulation of immune-related pathways.        
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Figure 35. Gene set enrichment analysis of differentially expressed genes between  
tumors with high burden of copy number loss and those with low burden of copy 
number loss. Gene set enrichment analysis (GSEA) results show top enriched KEGG 
pathways from down-regulated genes (blue bars) and up-regulated genes (red bars) in 
high burden of copy number loss group versus low burden of copy number loss group 
(FDR-adjusted P < 0.001). 
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Figure 36. Up and down-regulated pathways in patients with high versus low copy 
number loss in the Van Allen cohort. (A) Data show enrichment plots for top enriched 
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KEGG pathways from down-regulated genes (upper panel) and up-regulated genes 
(lower panel) in high burden of copy number loss group versus low burden of copy 
number loss group (FDR-adjusted P < 0.001). (B) Gene set enrichment analysis (GSEA) 
results show top enriched Gene Ontology (biological process) terms from down-
regulated genes (blue bar) and up-regulated genes (red bar) in high burden of copy 
number loss group versus low burden of copy number loss group (FDR-adjusted P < 
0.001). 
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4.2.5 Mutational load and burden of copy number loss may allow better 
patient stratification for response than either correlate alone 
 Finally, I was interested in determining if the effect of mutational load and 
burden of copy number loss on clinical response was non-redundant. Using the 
reanalyzed data from the Van Allen cohort, I first stratified patients into four 
subgroups based on mutational load (high or low) and burden of copy number 
loss (low or high) (Figure 37). Within each subgroup, I then calculated the 
proportion of patients with clinical benefit, long-term survival, and no clinical 
benefit, respectively (Figure 38). The proportion of patients with clinical benefit 
was higher in the subgroup of patients with high mutational load and low burden 
of copy number loss (11 out of 26) compared to the subgroup of patients with low 
mutational load and high burden of copy number loss (4 out of 26) (P = 0.064, 
Fisher’s exact test). Similarly, the proportion of patients with no clinical benefit 
was significantly higher in the subgroup of patients with low mutational load and 
high burden of copy number loss (21 out of 26) compared to the subgroup of 
patients with high mutational load and low burden of copy number loss (13 out of 
26) (P = 0.04, Fisher’s exact test). I then performed a logistic regression on 
response status (clinical response or no clinical response) with the log2-
transformed mutational load and log2-transformed burden of copy number loss as 
covariates, and found an additive effect of mutational load (coefficient = 0.266, z 
= 1.939, P = 0.053) and burden of copy number loss (coefficient = -0.149, z = -
2.55, P = 0.011) on clinical response (Table 15). This suggests that the effects of 
mutational load and burden of copy number loss on clinical response are likely 
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non-redundant. Collectively, the above data demonstrate the potential utility of a 
combinatorial biomarker using mutational load and copy number loss burden. 
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Figure 37. Patient stratification based on mutational load and burden of copy 
number loss in the Van Allen cohort. Patients were stratified into four subgroups 
based on mutational load and burden of copy number loss: high mutational load 
(>median, 220) and low burden of copy number loss (<=median, 1357) (n=26), high 
mutational load and high burden of copy number loss (n=23), low mutational load and 
low burden of copy number loss (n=23), and low mutational load and high burden of 
copy number loss (n=26). Within each subgroup, response status of each patient is 
color-coded.  
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Figure 38. Clinical response rate in patient subgroups stratified by mutational load 
and burden of copy number loss. Proportions of patients with clinical benefit, long-
term survival with no clinical benefit, and minimal or no clinical benefit were calculated 
within each of the four patient subgroups: high mutational load and low burden of copy 
number loss, high mutational load and high burden of copy number loss, low mutational 
load and low burden of copy number loss, and low mutational load and high burden of 
copy number loss. The numbers in parentheses indicate the number of patients with 
different levels of response (clinical benefit, long-term survival, and no clinical benefit) 
out of the total number of patients in each of the four patient subgroups.  
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Estimate Z)value P)value
Intercept !1.821 !1.556 0.12
Log2(Mutational9load) 0.266 1.939 0.053
Log2(Burden9of9copy9number9loss) !0.149 !2.55 0.011  
 
Table 15. Additive effect of high mutational load and low burden of copy number 
loss on response to CTLA-4 blockade. 
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4.3 Discussion 
        There is now abundant evidence that both tumor- (25, 41, 43, 44, 75, 119) 
and host-related factors (40, 59, 86, 120) can influence heterogeneous response 
and resistance to immune checkpoint blockade. Here, we report genomic 
characterization of tumors from a cohort of metastatic melanoma patients in the 
context of sequential immune checkpoint blockade. This study builds on our prior 
immune profiling of tumors within the same cohort of metastatic melanoma 
patients (87), allowing for a more fully integrated analysis in this particular cohort. 
In tumor compartment-specific analyses, we observed a higher burden of 
copy number loss in non-responders compared to responders on CTLA-4 
blockade. This finding is in line with those in prior studies that have reported that 
the burden of copy number alterations increases in advanced melanoma and is 
implicated in melanoma progression (148-151). The association between burden 
of copy number loss and clinical response observed here suggests that 
melanoma progression may be associated with resistance to immune mediated 
tumor control. Furthermore, investigation of the findings reported here in a first 
line treatment setting will help delineate the value of these potential associations.  
We also identified genomic regions of recurrent copy number loss in 
patients with high burden of copy number loss and determined that several tumor 
suppressor genes were located within these genomic regions. This suggests that 
loss of function in these tumor suppressor genes could potentially influence 
therapeutic resistance. In keeping with this suggestion, previous studies in 
preclinical models of melanoma with PTEN loss showed inhibition of T cell-
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mediated tumor killing and decrease in T cell trafficking into tumors (44). PTEN 
was one of the tumor suppressor genes with recurrent copy number loss from 
patients with high burden of copy number loss in this study as well. A correlation 
between copy number loss burden and down-regulation of immune-related gene 
expression was found, suggesting that there may be gene expression sequelae 
of extensive copy number loss, including PTEN loss. More extensive analyses on 
larger cohorts with matched WES and RNA-seq data are needed to expand on 
these findings and develop an integrated expression/copy number evaluation 
approach to validate and potentially exploit the correlation seen here. 
We also observed that the effects of low copy number loss burden and 
high mutational load on clinical response are non-redundant, suggesting the 
possibility of a combinatorial biomarker using copy number loss burden and 
mutational load. From a clinical perspective, the optimal cutoffs for high or low 
copy number loss burden and mutational load will need to be further validated if 
they are to impact improved patient stratification in the clinical setting.  
Our work also confirms previous reports that TCR clonality is correlated 
with response to PD-1 blockade (86). A combinatorial biomarker approach of 
TCR clonality and genomic correlates such as mutational load and copy number 
loss burden needs to be further tested in a large cohort with pre-PD-1 blockade 
biopsies available.  
Additionally, we observed increased TCR clonality after CTLA-4 blockade 
treatment in all PD-1 blockade responders with paired pre-CTLA-4 and pre-PD-1 
blockade biopsies available. Prior work has shown that TCR clonality at the pre-
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PD-1 time point was not significantly different (P = 0.1604) between anti-CTLA-4-
treated PD-1 blockade responders and anti-CTLA-4-naïve PD-1 blockade 
responders (86). Therefore, CTLA-4 blockade treatment may increase TCR 
clonality to a level high enough to mediate response to subsequent PD-1 
blockade in certain patients. This result suggests that responders to PD-1 
blockade may derive clinical benefit from prior CTLA-4 blockade, substantiating 
the utility of sequential CTLA-4 and PD-1 blockade. From a clinical perspective, 
sequential CTLA-4 and PD-1 blockade treatment might be able to increase the 
number of patients with high baseline TCR clonality prior to PD-1 blockade 
compared with PD-1 blockade monotherapy. 
What emerges from this and other work regarding immune checkpoint 
responder/non-responder identification is a complex picture likely involving the 
interplay of tumor genomic characteristics, tumor modulation of the local 
microenvironment, and the extent of immune surveillance in the tumor milieu at 
the time of initiation of therapy. Furthermore, several intriguing questions emerge 
from this and other work. What is the effect of CTLA-4 blockade on the molecular 
profile of anti-PD-1 responders? Do the data reported hold true when applied to 
CTLA-4 blockade treatment-naïve patients? To what extent do the data emerging 
from melanoma studies apply to other tumor treatment contexts? There will likely 
be a need to develop integrated molecular phenotyping approaches to more 
accurately delineate responders/non-responders and develop tractable predictive 
models for these promising therapies.  
 
 
	   141	  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE – DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   142	  
Chapter 5 DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Discussion and Conclusions 
        The recent development of immunotherapy and cancer immunogenomics 
has changed the treatment landscape in metastatic melanoma. Immune 
checkpoint blockade has now become the front-line treatment for melanoma 
demonstrating prolonged survival and durable response. However, the response 
rate and the toxicity vary among individuals. Therefore, biomarkers are needed to 
predict patients who are more likely to respond and experience lower toxicity. In 
addition to biomarker discovery, identifying mechanisms of resistance to immune 
checkpoint blockade can further the development of novel combination therapy 
increasing the response rate. In this dissertation, I attempted to identify novel 
biomarkers and resistance mechanisms of immune checkpoint blockade (CLTA-4 
and PD-1 blockade) by performing multidimensional profiling of longitudinal 
tumor biopsies (pre-, on-, and post-treatment) from metastatic melanoma 
patients treated with sequential immune checkpoint blockade.  
        In Chapter 3, we applied the immune profiling approach by 
immunohistochemistry staining of 12 markers and NanoString Gene Expression 
Profiling of 795 tumor microenvironment gene panels composed of immune-
related genes and common cancer signaling pathway genes. The 
characterization of tumor microenvironment at multiple time points revealed that 
early on-treatment (as early as 2 to 3 doses after PD-1 blockade treatment) 
tumor biopsies show significantly increased expression of adaptive immune 
signature in responders versus nonresponders. This observation suggests that 
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assessment of adaptive immune signatures by early on-treatment biopsies can 
help identify patients who will respond to PD-1 blockade. By predicting response 
at early on-treatment time point, we can reduce the unnecessary burden of 
treatment cost and toxicity in patients who are not likely to respond to PD-1 
blockade. Another major finding of immune profiling was that VEGFA expression 
was significantly higher in nonresponders versus responders in PD-1 blockade 
on-treatment biopsies suggesting the potential mechanism of therapeutic 
resistance mediated by tumor angiogenesis. Our finding is consistent with the 
results from the recent preclinical studies showing the efficacy of combination 
therapy of PD-1 blockade and antiangiogenic therapy (152,	  153). Several clinical 
trials of combined PD-1 blockade and antiangiogenic therapy are also ongoing, 
and a phase I study combining bevacizumab and ipilimumab showed an 
objective response rate of 19.6% and a median survival of 25.1 months, which is 
roughly twice expectation for ipilimumab monotherapy in metastatic melanoma (109,	   154). Additionally, we observed the increased intratumoral interaction 
between CD8+ T cells and CD68+ myeloid cells in both pre-treatment and on-
treatment biopsies from nonresponders to PD-1 blockade. A recent study 
showed that tumor-associated macrophages (TAMs) physically remove the anti-
PD-1 antibodies from the surface of T cells, which leads to resistance to PD-1 
blockade treatment (51). They also showed that uptake of anti-PD-1 antibodies 
by TAMs depends on the crystallizable fragment (Fc) domain of the anti-PD-1 
monoclonal antibodies and on Fcγ receptors (FcγRs) expressed by TAMs. This 
mechanism might explain why nonresponders to PD-1 blockade have the 
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increased intratumoral interaction between CD8+ T cells and CD68+ myeloid 
cells. This finding suggests that combining PD-1 blockade with blockade of Fcγ 
receptors (FcγRs) might be therapeutically effective in metastatic melanoma 
patients with increased intratumoral interaction between CD8+ T cells and 
CD68+ myeloid cells. 
        However, there are some caveats and biases in interpreting immune 
profiling data in our study. First, identifying an immune cell subset based on the 
staining of one marker using immunohistochemistry can bias the quantification of 
immune cell subset proportion in tumor microenvironment. Multiplexed marker 
imaging approach such as Vectra would provide more unbiased picture of 
immune cell subset representation in a tissue. Second, NanoString tumor 
microenvironment gene panels cannot capture the unbiased genome-wide 
transcriptome profiles in the tumor microenvironment because the composition of 
gene panels is based on immune-related genes. Therefore, RNA-seq data would 
have provided unbiased enrichment of certain pathways in differential gene 
expression analysis and analysis of differential longitudinal gene expression 
change between responders and nonresponders by linear mixed effects model. 
        In Chapter 4, we performed genomic profiling of tumor biopsies from the 
same cohort of patients in Chapter 3. TCR sequencing of tumor biopsies showed 
higher TCR clonality in responders versus nonresponders at pre-/on-PD-1 
blockade time point. This result suggests that pre-existing clonal T clones 
actively suppressed in tumor microenvironment are crucial in mediating antitumor 
response after PD-1 blockade treatment. We also observed increased TCR 
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clonality after CTLA-4 blockade treatment in all PD-1 blockade responders 
whereas this longitudinal TCR clonality pattern could not be observed in 
nonresponders. This data suggest that prior CTLA-4 blockade treatment can be 
beneficial for subset of patients by preparing clonal baseline T cell repertoire in 
tumor microenvironment for the success of subsequent PD-1 blockade treatment.  
        Analysis of whole exome sequencing data revealed the novel tumor-intrinsic 
resistance mechanism driven by high burden of copy number loss in tumors. Of 
note, recurrent copy number loss was observed in certain genomic regions (arm 
level loss in 6q and 10q) contributing to major therapeutic resistance. 
Mechanistically, tumors with high burden of copy number loss showed decreased 
expression of immune-related genes. Our finding is consistent with the result 
from an independent study showing that tumor aneuploidy is associated with 
immune evasion in multiple cancer types (155). Since aneuploidy is associated 
with worse prognosis in general, it would be of interest to investigate the extent to 
which resistance to immune checkpoint blockade leads to worse prognosis in 
patients with high burden of copy number loss (156). Finally, I showed that 
combining burden of copy number loss with mutational load provided better 
predictive power than either alone. 
        However, there were some technical difficulties in the analysis of genome 
profiling data. First, the detection of CNAs in tumors with high level of tumor-
infiltrating lymphocytes is challenging due to low sensitivity to detect CNAs in low 
tumor purity samples by current CNA detection algorithms. Therefore, the 
observation of higher immune cell infiltration in tumors with lower burden of copy 
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number loss might have been confounded by this technical limitation to some 
extent. Single cell exome sequencing of tumor cells with varying degree of 
immune cell infiltration would provide more accurate relationship between tumor 
aneuploidy and immune evasion. Second, it is difficult to extract accurate tumor-
intrinsic transcriptome profiles from the bulk tumor RNA-seq data. Therefore, 
differential gene expression profiles between tumors with high versus low copy 
number loss might have not captured important tumor-intrinsic differentially 
expressed genes. Single-cell RNA-seq of tumor cells would provide more 
accurate tumor-intrinsic differential transcriptome profiles between tumor cells 
with high versus low burden of copy number loss because arm level loss can be 
computationally detected from single-cell RNA-seq data. Differential gene 
expression analysis of single-cell RNA-seq data might shed light on the detailed 
mechanism of immune evasion by tumor aneuploidy.   
        In conclusion, our study is one the first longitudinal studies investigating the 
molecular interplay between immune cells and tumor cells in the context of 
sequential immune checkpoint blockade treatment. First, I could identify 
biomarkers to PD-1 blockade such as early on-treatment adaptive immune 
signatures, clonal T cell repertoire in tumor microenvironment, and increase in 
TCR clonality after CTLA-4 blockade treatment. The combinatory biomarker 
approach of mutational load and burden of copy number loss was also 
suggested. Second, I identified resistance mechanisms such as increased 
VEGFA expression in nonresponders to PD-1 blockade and the association 
between higher burden of copy number loss and immune evasion leading to lack 
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of response. Our study sets the framework for discovery of novel biomarkers and 
resistance mechanisms of immune checkpoint blockade by integrative and 
longitudinal analysis of genomic and immune components. 
         
5.2 Future Directions 
        Immune profiling results showed that early adaptive immune signatures 
could be observed in responders in Chapter 3. Interestingly, previous study 
reported that early on-treatment biopsies (n=21) within 2 months from initiation of 
PD-1 blockade treatment showed a significant infiltration of intratumoral CD3+, 
CD8+, and CD68+ macrophages in responders, but not in nonresponders (157).	  
Therefore, it would be interesting to determine how early these adaptive immune 
signatures can be observed in responders after treatment, which will allow 
nonresponders to change with other treatment options. This early biomarker will 
reduce the unnecessary treatment cost and toxicity from patients.  
        Additionally, it would be of interest to investigate whether early adaptive 
immune signatures can also be seen in other solid cancers. However, it is often 
more difficult to obtain post-treatment samples in other solid cancers. The recent 
study showed that tumor-infiltrating CD8+ T cells with neoantigen specificity can 
express PD-1 and the same PD-1 expressing T cells can also be found in the 
blood of melanoma patients (158). Therefore, we might be able to use liquid 
biopsy as a post-treatment monitoring tool and investigate whether early adaptive 
immune signatures can be observed in the blood.  
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        In Chapter 3, spatial analysis of immunohistochemistry data revealed 
differential ratio of CD8+ T cells at the tumor center versus margin between 
responders and nonresponders. It might be interesting to compare transcriptional 
state between CD8+ T cells at the tumor center and those at the tumor margin by 
spatially resolved single-cell RNA-seq in intact tissues. 
        From longitudinal analysis of TCR sequencing data, I observed increased 
TCR clonality in subset of patients after CTLA-4 blockade treatment. This 
increase in TCR clonality was high enough to mediate response to subsequent 
PD-1 blockade treatment. From a clinical perspective, it would be useful to know 
which patients will be more likely to experience increase TCR clonality after 
CTLA-4 blockade treatment. Such biomarkers will then be used as a screening 
tool for sequential CTLA-4 and PD-1 blockade treatment.  
        Finally, our study shows that both immune and tumor component plays a 
critical role in response and resistance to immune checkpoint blockade. For 
example, pre-existing clonal T cell clones in tumor microenvironment were 
associated with better response to PD-1 blockade whereas tumors with higher 
burden of copy number loss showed lower immune cell infiltration leading to lack 
of response. The dynamic change in immune component also contributed to 
response and resistance. Increased expression of VEGFA in nonresponders to 
PD-1 blockade at on-treatment time point showed adaptive resistance to PD-1 
blockade. On the other hand, increase in TCR clonality after CTLA-4 blockade 
treatment was associated with response to PD-1 blockade. Therefore, integrative 
analysis of immune and tumor component at both pre-treatment time point and 
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on-/post-treatment time point should be performed for biomarker discovery and 
identification of resistance mechanisms. In future studies, we need to take two 
different integrative analysis approaches for deeper understanding of cancer 
immunology as well as clinical utility of biomarkers. The first approach would be 
to understand mechanistic link between immune and tumor component in the 
context of immune checkpoint blockade. A large number of studies have found 
many potential biomarkers of response and resistance to immune checkpoint 
blockade. However, few studies have investigated the correlation between those 
biomarkers and their mechanistic link. Deeper understanding of relationship 
between biomarkers might provide new insights into cancer immunology. The 
second approach would be to build a predictive model based on immune and 
tumor component in a large cohort. This will allow us to find the most predictive 
combination and relative importance of each immune and tumor component in 
predicting response to immune checkpoint blockade. The predictive model 
trained with all the known biomarkers in a large cohort of patients will provide the 
robust clinical framework for treatment guidance of this therapy. 
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